UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

⌧	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30, 2022~~March 31, 2023

◻	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-36464

Agile Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	23-2936302
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

500 College Road East, Suite 300

Princeton, New Jersey 08540

(Address including zip code of principal executive offices)

(609) 683-1880

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of exchange on which registered:
Common stock, par value $0.0001 per share	AGRX	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻	Accelerated filer ◻

Non-accelerated filer ⌧	Smaller reporting company ⌧

	Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ◻ No ⌧

There were ~~40,614,527~~988,975 shares of the registrant’s common stock, $0.0001 par value, outstanding as of ~~November 4, 2022.~~May 8, 2023.

Table of Contents

Agile Therapeutics, Inc.

Quarterly Report on Form 10-Q

For the Quarter Ended ~~September 30, 2022~~March 31, 2023

~~Table of Contents~~


Special Cautionary Notice Regarding Forward Looking Statements	3
PART I: FINANCIAL INFORMATION	6
Item 1. Financial Statements	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	2526
Item 3. Quantitative and Qualitative Disclosures About Market Risk	3835
Item 4. Controls and Procedures	3836

PART II: OTHER INFORMATION
Item 1. Legal Proceedings	3937
Item 1A. Risk Factors	3937
Item 6. Exhibits	4038

Table of Contents

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “designed,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our current intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned manufacturing and commercialization of Twirla^®, the potential market acceptance and uptake of Twirla^®, including the level of reimbursement available from third-party payors, the development of our other potential product candidates, the attractiveness of our business to potential investors or business partners, the strength and breadth of our intellectual property, our ~~ongoing and~~ planned clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our potential product candidates, the legal and regulatory landscape impacting our business, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and ~~strategies, including expense reduction~~ strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods.

Some of the factors that we believe could cause actual results to differ from those anticipated or predicted include:

●

our available cash and our ability to obtain additional funding to fund our business plan without delay and to continue as a going concern;

●

our ability to successfully maintain and enhance the commercialization of and increase the uptake for Twirla, our only approved product;

●

the rate and degree of market acceptance of Twirla by physicians, patients, clinics, institutions, third-party payors and others in the healthcare community;

●our ability to obtain adequate coverage and reimbursement for Twirla in the United States from private and public third-party payors;

●

the size and growth of the markets for Twirla and our ability to serve those markets;

●

~~the effects~~shortages of key materials in the ~~ongoing COVID-19 pandemic on our commercialization efforts, clinical trials,~~ supply chain ~~operations~~implicating the manufacture and ~~the operations~~distribution of ~~third parties we rely on for services such as manufacturing, marketing support and sales support, as well as the effects of the COVID-19 pandemic on our potential customer base;~~Twirla;

●

regulatory and legislative developments in the United States and foreign countries, which could include, among other things, a government ~~shutdown;~~shutdown or limiting access to prescription contraceptives;

●

the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;

Table of Contents

●

~~The~~the growth in demand for Twirla and our ability to manage the levels of Twirla inventory, which could result in our having to write off inventory and our inability to meet the minimum requirements under our supply agreement with ~~Corium.~~Corium Pharma Solutions (“Corium”);

●

our ability to timely obtain from our third-party manufacturer, Corium, sufficient quantities or quality of Twirla or other materials required for a clinical trial or other tests and studies;

●

the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla;

●

the performance and financial condition of Corium or any of the suppliers;

●

our ability to design and successfully complete a post-marketing long-term, prospective observational safety study comparing risks for venous thromboembolism, or VTE, and arterial thromboembolism, or ATE, in new users of Twirla to new users of oral combined hormonal contraceptives, or CHCs, and new users of Xulane in U.S. women of reproductive age using CHCs and ~~successfully complete a~~the outcomes of our discussions with the United States Food and Drug Administration, or FDA, regarding the results of our post-marketing commitment, or PMC, to assess the residual drug content of Twirla after use;

●

our ability to maintain regulatory approval of Twirla and the labeling under any approval we obtain;

●

our ability to obtain and maintain intellectual property protection for Twirla and our product candidates;

●

the success and timing of our clinical trials or other studies, including post-marketing studies for Twirla;

●

development of unexpected safety or efficacy concerns related to Twirla;

●

our ability to continue to develop and maintain successful sales and marketing capabilities, including our ability to maintain an effective sales force or failure to build-out and implement an effective health care compliance program;

●

our ability to come into compliance with the listing requirements of the Nasdaq Capital Market;

●

our ability to retain key employees and recruit the additional personnel we will need to support our commercialization plan for Twirla; and

●

our ability to successfully implement our strategy.

Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q. You should also read carefully the factors described in the “Risk Factors” included in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021~~2022 filed with the Securities and Exchange Commission on March ~~30, 2022~~23, 2023 to better understand significant risks and uncertainties inherent in our business and underlying any forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, any such inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard any of these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.

This Quarterly Report on Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys, and studies are reliable, we have not independently verified such data.

Table of Contents

We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Twirla^®is one of our trademarks used in this Form 10-Q. This Form 10-Q also includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this Form 10-Q may appear without the ® symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.

Table of Contents

Agile Therapeutics, Inc.

Part I — Financial Information

ITEM 1. Financial Statements

Agile Therapeutics, Inc.

Balance Sheets

(Unaudited)

(in thousands, except par value and share data)


	September 30,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
Assets
Current assets:
Cash and cash equivalents	$	6,145	$	19,143	$	4,429	$	5,246
Accounts receivable, net		3,711		1,533		3,123		3,377
Inventory, net		1,797		966		2,211		1,332
Prepaid expenses and other current assets		3,834		2,283		1,143		1,403
Total current assets		15,487		23,925		10,906		11,358
Property and equipment, net		203		12,447		151		177
Right of use asset		761		949		628		695
Other non-current assets		2,012		2,012		2,012		2,012
Total assets	$	18,463	$	39,333	$	13,697	$	14,242

Liabilities and stockholders’ equity
Liabilities and stockholders’ deficit
Current liabilities:
Long-term debt, current portion	$	1,318	$	16,833	$	1,508	$	1,426
Accounts payable		4,906		8,707		10,358		7,734
Accrued expenses		5,152		3,563		6,310		3,908
Lease liability, current portion		277		175		330		319
Total current liabilities		11,653		29,278		18,506		13,387

Lease liabilities, long-term		550		784		378		466
Long-term debt		—		—
Warrant liability						4,247		5,934
Total liabilities		12,203		30,062		23,131		19,787
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at September 30, 2022 and no shares issued and outstanding at December 31, 2021		—		—
Common stock, $.0001 par value, 300,000,000 shares authorized, 39,026,823 and 3,034,901 issued and outstanding at September 30, 2022 and December 31, 2021, respectively		4		—
Stockholders’ deficit
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at March 31, 2023 and no shares issued and outstanding at December 31, 2022						—		—
Common stock, $0.0001 par value, 300,000,000 shares authorized, 932,101 and 859,402 issued and outstanding at March 31, 2023 and December 31, 2022, respectively						—		—
Additional paid-in capital		437,027		396,388		404,658		403,157
Accumulated deficit		(430,771)		(387,117)		(414,092)		(408,702)
Total stockholders’ equity		6,260		9,271
Total liabilities and stockholders’ equity	$	18,463	$	39,333
Total stockholders’ deficit						(9,434)		(5,545)
Total liabilities and stockholders’ deficit					$	13,697	$	14,242

See accompanying notes to unaudited financial statements.

Table of Contents

Agile Therapeutics, Inc.

Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except per share and share data)


	Three Months Ended				Nine Months Ended
	September 30,				September 30,				March 31,
	2022		2021		2022		2021		2023		2022

Revenues, net	$	3,002	$	1,287	$	6,888	$	2,587	$	3,813	$	1,761
Cost of product revenues		1,425		2,711		5,183		5,017		2,003		1,527
Gross profit (loss)		1,577		(1,424)		1,705		(2,430)
Gross profit										1,810		234

Operating expenses:
Research and development	$	788	$	1,593	$	2,901	$	4,568	$	763	$	1,257
Selling and marketing		5,560		9,386		23,523		30,263		4,670		10,553
General and administrative		2,815		3,371		9,837		11,386		3,085		3,997
Loss on disposition of assets		11,122		—		11,122		—
Total operating expenses		20,285		14,350		47,383		46,217		8,518		15,807
Loss from operations		(18,708)		(15,774)		(45,678)		(48,647)		(6,708)		(15,573)

Other income (expense)
Interest income		46		1		50		24		33		1
Interest expense		(1,004)		(999)		(2,699)		(2,914)		(402)		(872)
Total other income (expense), net		(958)		(998)		(2,649)		(2,890)
Unrealized gain on warrant liability										1,687		1,384
Total other income, net										1,318		513
Loss before benefit from income taxes		(19,666)		(16,772)		(48,327)		(51,537)		(5,390)		(15,060)
Benefit from income taxes		—		—		4,675		—		—		4,675
Net loss	$	(19,666)	$	(16,772)	$	(43,652)	$	(51,537)
Net loss and comprehensive loss									$	(5,390)	$	(10,385)

Net loss per share (basic and diluted)	$	(0.53)	$	7.20	$	(2.91)	$	(22.80)	$	(5.91)	$	(166.68)

Weighted-average common shares (basic and diluted)		36,997,836		2,343,930		14,998,534		2,251,205		912,044		62,304

Comprehensive loss:
Net loss	$	(19,666)	$	(16,772)	$	(43,652)	$	(51,537)
Other comprehensive income:
Unrealized loss on marketable securities		—		—		—		(3)
Comprehensive loss	$	(19,666)	$	(16,772)	$	(43,652)	$	(51,540)

See accompanying notes to unaudited financial statements.

Table of Contents

Agile Therapeutics, Inc.

Statements of Changes in Stockholders’ Deficit

(Unaudited)

(in thousands, except share data)


	Preferred Stock			Common Stock			Additional		Accumulated				Total
	Number of			Number of			Paid-in		Other Comprehensive		Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Capital		Income		Deficit		Deficit
Balance December 31, 2022	—	$	—	859,402	$	—	$	403,157	$	—	$	(408,702)	$	(5,545)
Share-based compensation - stock options and RSUs	—		—	—		—		498		—		—		498
Issuance of common stock pursuant to at-the market stock sales, net of expenses	—		—	72,699		—		1,003		—		—		1,003
Net loss	—		—	—		—		—		—		(5,390)		(5,390)
Balance March 31, 2023	—	$	—	932,101	$	—	$	404,658	$	—	$	(414,092)	$	(9,434)

See accompanying notes to unaudited financial statements.

On April 10, 2023, the Company effectuated a one-for-fifty reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduces the Company’s shares of outstanding common stock, stock options, RSU’s, and warrants to buy shares of the Company’s common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share, and cash in lieu payments were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.

Agile Therapeutics, Inc.

Statements of Changes in Stockholders' Equity (Deficit)

(Unaudited)

(in thousands, except share data)


	Preferred Stock			Common Stock			Additional		Accumulated				Total		Preferred Stock			Common Stock			Additional		Accumulated				Total
	Number of			Number of			Paid-in		Other Comprehensive		Accumulated		Stockholders'		Number of			Number of			Paid-in		Other Comprehensive		Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Capital		Income		Deficit		Equity		Shares	Amount		Shares	Amount		Capital		Income		Deficit		Deficit
Balance December 31, 2021	—	$	—	3,034,901	$	—	$	396,388	$	—	$	(387,117)	$	9,271	—	$	—	60,698	$	—	$	387,205	$	—	$	(383,290)	$	3,915
Share-based compensation - stock options and RSUs	—		—	—		—		764		—		—		764	—		—	—		—		764		—		—		764
Issuance of common stock pursuant to at-the market stock sales, net of expenses	—		—	25,623		—		348		—		—		348	—		—	512		—		348		—		—		348
Issuance of series A and B convertible preferred stock in a registered direct offering (Note 8)	4,850		4,850	—		—		—		—		—		4,850	4,850		—	—		—		—		—		—		—
Registered direct financing costs, inclusive of warrants			(965)					244		—		—		(721)
Conversion of series A convertible preferred stock	(2,425)		(897)	303,125		—		897		—		—		—			—	6,063		—		—		—		—		—
Vesting of RSUs	—		—	1,773		—		—		—		—		—	(2,425)		—	35		—		—		—		—		—
Warrants issued in connection with registered direct offering	—		(2,101)	—		—		2,101		—		—		—
Net loss	—		—	—		—		—		—		(11,769)		(11,769)	—		—	—		—		—		—		(10,385)		(10,385)
Balance March 31, 2022	2,425	$	887	3,365,422	$	—	$	400,742	$	—	$	(398,886)	$	2,743	2,425		—	67,308	$	—	$	388,317	$	—	$	(393,675)	$	(5,358)
Share-based compensation - stock options and RSUs	—		—	—		—		669		—		—		669
Fractional shares retired as a result of reverse split	—		—	(10)		—		—		—		—		—
Issuance of common stock pursuant to at-the market stock sales, net of expenses	—		—	8,687,502		1		12,225		—		—		12,226
Conversion of series B convertible preferred stock	(2,425)		(887)	303,125		—		887		—		—		—
Vesting of RSUs	—		—	4,118		—		—		—		—		—
Net loss	—		—	—		—		—		—		(12,219)		(12,219)
Balance June 30, 2022	—	$	—	12,360,157	$	1	$	414,523	$	—	$	(411,105)	$	3,419
Share-based compensation - stock options and RSUs	—		—	—		—		536		—		—		536
Issuance of common stock pursuant to a public offering, net of expenses	—		—	26,666,666		3		21,968		—		—		21,971
Net loss	—		—	—		—		—		—		(19,666)		(19,666)
Balance September 30, 2022	—		—	39,026,823	$	4	$	437,027	$	—	$	(430,771)	$	6,260

See accompanying notes to unaudited financial statements.

~~Table of Contents~~

~~Agile Therapeutics, Inc.~~

~~Statements of Changes in Stockholders' Equity~~

~~(Unaudited)~~

~~(in thousands, except share data)~~

Common Stock

Additional

Accumulated

Total

Number of

Paid-in

Other Comprehensive

Accumulated

Stockholders'


Shares

Amount

Capital

Income

Deficit

Equity
Balance December 31, 2020

2,189,094

$
—

$
361,548

$
3

$
(312,223)

$
49,328
Share-based compensation - stock options and RSUs

—

—

742

—

—

742
Issuance of common stock pursuant to at-the market stock sales, net of expenses

13,023

—

960

—

—

960
Issuance of common stock upon exercise of stock options

3,160

—

75

—

—

75
Vesting of RSUs

1,316

—

—

—

—

—
Warrants issued in connection with long-term debt

—

—

1,080

—

—

1,080
Unrealized net gain on marketable securities

—

—

—

(3)

—

(3)
Net loss

—

—

—

—

(17,128)

(17,128)
Balance March 31, 2021

2,206,593

$
—

$
364,405

$
—

$
(329,351)

$
35,054
Share-based compensation - stock options and RSUs

—

—

843

—

—

843
Issuance of common stock pursuant to at-the market stock sales, net of expenses

114,826

—

6,349

—

—

6,349
Vesting of RSUs

1,786

—

—

—

—

—
Unrealized net gain on marketable securities

—

—

—

—

—

—
Net loss

—

—

—

—

(17,637)

(17,637)
Balance June 30, 2021

2,323,205

$
—

$
371,597

$
—

$
(346,988)

$
24,609
Share-based compensation - stock options and RSUs

—

—

887

—

—

887
Issuance of common stock pursuant to at-the market stock sales, net of expenses

45,030

—

1,956

—

—

1,956
Unrealized net gain on marketable securities

—

—

—

—

—

—
Net loss

—

—

—

—

(16,772)

(16,772)
Balance September 30, 2021

2,368,235

$
—

$
374,440

$
—

$
(363,760)

$
10,680

~~See accompanying notes to unaudited financial statements.~~

Table of Contents

Agile Therapeutics, Inc.

Statements of Cash Flows

(Unaudited)

(in thousands)


	Nine Months Ended				Three Months Ended
	September 30,				March 31,
	2022		2021		2023		2022
Cash flows from operating activities:
Net loss	$	(43,652)	$	(51,537)	$	(5,390)	$	(10,385)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash inventory reserve		—		1,415
Depreciation		1,255		1,546		26		527
Amortization		188		102		67		61
Loss on disposition of assets		11,122		—
Noncash stock-based compensation		1,969		2,472		498		764
Noncash amortization of deferred financing costs		1,635		1,262		307		419
Unrealized gain on warrants						(1,687)		(1,384)
Changes in operating assets and liabilities:
Accounts receivable		(2,178)		(444)		254		(132)
Income taxes receivable						—		(4,675)
Inventory		(831)		(4,875)		(879)		(1,727)
Prepaid expenses and other assets		(1,551)		(885)		260		707
Accounts payable and accrued expenses		(2,213)		2,462		5,026		1,095
Lease liability		(132)		(102)		(77)		(21)
Net cash used in operating activities		(34,388)		(48,584)		(1,595)		(14,751)

Cash flows from investing activities:
Sales and maturities of marketable securities		—		39,729
Acquisition of property and equipment		(133)		(214)		—		(126)
Net cash (used in) provided by investing activities		(133)		39,515		—		(126)

Cash flows from financing activities:
Proceeds from issuance of preferred stock in registered direct offering, net of offering costs		4,129		—		—		4,129
Proceeds from issuance of common stock in public offering, net of offering costs		21,971		—
Proceeds from At-the-Market sales of common stock, net of offering costs		12,573		9,266		1,003		348
Repayments of long-term debt		(17,150)		—		(225)		(5,000)
Proceeds from exercise of stock options		—		75
Net cash provided by financing activities		21,523		9,341
Net cash provided by (used in) financing activities						778		(523)

Net (decrease) increase in cash and cash equivalents		(12,998)		272
Net decrease in cash and cash equivalents						(817)		(15,400)
Cash and cash equivalents, beginning of period		19,143		14,463		5,246		19,143
Cash and cash equivalents, end of period	$	6,145	$	14,735	$	4,429	$	3,743

Supplemental disclosure of noncash financing activities
Warrants issued in connection with long-term debt	$	—	$	1,080
Warrants issued in connection with preferred stock offering		2,101		—
Conversion of Series A preferred stock into common stock		897		—
Conversion of Series B preferred stock into common stock		887		—
Supplemental cash flow information
Interest paid	$	1,078	$	1,782	$	94	$	452

See accompanying notes to unaudited financial statements.

109

Table of Contents

1. Organization and Description of Business

Nature of Operations

Agile Therapeutics, Inc. (“Agile” or the “Company”) was incorporated in Delaware on December 22, 1997. Agile is a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. The Company’s activities since inception have consisted principally of raising capital, performing research and development, including development of the Company’s lead product, Twirla^®, and more recently commercializing Twirla. The Company is headquartered in Princeton, New Jersey.

The Company’s sole approved product, Twirla, ~~also known prior to its approval as AG200-15,~~ is a once-weekly prescription contraceptive patch that received approval from the U.S. Food and Drug Administration, or FDA, in February 2020 and was commercially launched in early December 2020. Substantially all of the Company’s resources are currently dedicated to commercializing Twirla in the United States. The Company has generated minimal product revenue to date and is subject to a number of risks similar to those of other early stage commercial companies, including, but not limited to, dependence on key individuals, the difficulties and uncertainties inherent in the development of commercially usable products, market acceptance of products, protection of proprietary technology, the potential need to obtain additional capital necessary to fund the development of its products, reliance on a consistent supply chain both for Twirla and in general, macroeconomic factors such as inflation,, competition from larger companies, and compliance with FDA and other government regulations. If the Company does not successfully commercialize Twirla, it will be unable to generate recurring product revenue or achieve profitability. The Company has incurred operating losses and negative cash flows from operating activities each year since inception. As of ~~September 30, 2022,~~March 31, 2023, the Company had an accumulated deficit of approximately $~~431~~414.1 million.

The Company expects to continue to incur significant operating expenses for the foreseeable future in connection with its ongoing activities, as the Company:

●

maintains a sales and marketing infrastructure and contract manufacturing arrangement to support the continued commercialization of Twirla in the United States;

●

continues to commercialize Twirla and seek increased uptake of Twirla in the United States;

●

~~works towards completing its post-marketing evaluations of Twirla agreed upon with the FDA upon Twirla’s approval;~~

●

continues to evaluate additional line extensions for Twirla and initiates development of potential product candidates in addition to Twirla;

●

maintains, leverages, and expands the Company’s intellectual property portfolio; and

●

maintains operational, financial, and management information systems and personnel, including personnel to support the Company’s product development and future commercialization efforts.

The Company has financed its operations to date primarily through the issuance and sale of its common stock in both public and private offerings (see Note 8), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding.

Going Concern

As of ~~September 30, 2022,~~March 31, 2023, the Company had cash and cash equivalents of ~~$6.1~~ $4.4 million and a $7.6~~million.~~ ~~We believe our~~ million working capital deficit. The Company’s current liquidity is sufficient to fund operations into June 2023. The Company closely monitors its cash and cash equivalents and will ~~support operations~~need to raise additional funds to meet its projected operating requirements, including the continued commercialization of Twirla, and exploring the advancement of its existing pipeline and its possible expansion through ~~December 31, 2022.~~

business development activities.

The Company has generated losses since inception, used substantial cash in operations, has a working capital deficit at March 31, 2023, and anticipates it will continue to incur net losses for the foreseeable future. The Company’s future success depends on its ability to obtain additional capital and/or implement various strategic alternatives, and there can be no assurance that any financing can be realized by the Company, or if realized, what the terms of any such financing may be, or that any amount that the Company is able to raise will be adequate. ~~If the Company is unable to obtain funds when needed or on acceptable terms, the Company then will be unable to continue the commercialization of Twirla, and be required to~~

~~Table of Contents~~

~~cut operating costs, and forego future development and other opportunities.~~ Based upon the foregoing, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern through the 12 months following the date on which this Quarterly Report on Form 10-Q is filed.

Table of Contents

The Company continues to analyze various alternatives, including refinancing alternatives, asset sales and mergers and acquisitions. The Company’s future success depends on its ability to raise additional capital as discussed above. The Company cannot be certain that these initiatives, or raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current stockholders will experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company then may be unable to continue the commercialization of Twirla, and may also be required to cut operating costs, and forego future development and other opportunities.

The unaudited financial statements as of ~~September 30, 2022~~March 31, 2023 have been prepared under the assumption that the Company will continue as a going concern for the next 12 months. The Company’s ability to continue as a going concern is dependent upon its uncertain ability to obtain additional capital, reduce expenditures and/or execute on its business plan and successfully commercialize Twirla. The unaudited financial statements as of March 31, 2023 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements.

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for ~~reporting~~Quarterly Reports on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 as filed with the SEC on March ~~30, 2022.~~23, 2023.

In the opinion of management, the unaudited interim financial statements reflect all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods presented. The results of operations for the three ~~and nine~~ months ended ~~September 30, 2022~~March 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period.

Theaccompanying unaudited financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations. If the ~~COVID-19 pandemic or other~~Company encounters unforeseen factors that impact the Company’s current business plan or its ability to generate revenue from the ~~launch~~commercialization of Twirla, the Company believes it has the ability to revise its commercial plans, including curtailing sales and marketing spending, to allow it to continue to fund its ~~operations~~operations.

2. Summary of Significant Accounting Policies

The Company’s complete listing of significant accounting policies is described in Note 2 to the Company’s audited financial statements as of December 31, ~~2021~~2022 included in its Annual Report on Form 10-K filed with the SEC on March ~~30, 2022.~~

~~Reverse Stock Split~~

~~On April 26, 2022, the Company effectuated a~~ ~~one~~-for-forty reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduces the Company’s shares of outstanding common stock, stock options, RSUs, and warrants to buy shares of our common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of payments were made to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.23, 2023.

Use of Estimates

The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, costs of product revenues, inventory reserves, the accounting for common stock warrants, stock-based compensation, and accounting for

1211

Table of Contents

research and development costs. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates.

Risks and Uncertainties

While Twirla has been approved by the ~~U.S. Food and Drug Administration, or~~ FDA, other potential product candidates developed by the Company will require approval from the FDA prior to commercial sales. There can be no assurance that the Company’s other product candidates will receive the required approval. If the Company is denied approval or such approval is delayed, or is unable to obtain the necessary financing to complete development and approval, there could be a material adverse impact on the Company’s financial condition and results of operations.

It should be noted that ~~current~~the possibility of continued public health threats could adversely affect the Company’s ongoing or planned business operations. ~~In particular,~~For example, the ~~ongoing COVID-19~~coronavirus (“COVID-19”) pandemic ~~has~~previously resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The most significant impacts to the Company’s business were encountered by sales representatives promoting Twirla in the field, as some offices limited opportunities for face-to-face interactions with healthcare providers. ~~In many cases~~Re-implementation of COVID-19 ~~restrictions have recently eased, but re-implementation of such~~ restrictions, if necessary in the future, may disrupt the Company’s business and/or could adversely affect the Company’s commercialization plans and results. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties with whom itthe Company engages, including personnel at third-party manufacturing facilities and other third parties with whom the Company conducts business, were to experience shutdowns or other business disruptions, the Company’s ability to conduct its business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on the Company. While to date the Company has been able to continue to execute its overall business plan, some of its business activities slowed and took longer to complete as the Company adjusted to the challenges of operating in a largely remote setting with its employees. While the Company has acclimated to a hybrid work model with its employees, anotherAnother shut down necessitating work in a completely remote environment could result in delays to its business activities and commercialization plan. ~~Overall, the~~The Company ~~recognizes the challenges of commercializing a new product in a pandemic, and it~~ will continue to closely monitor events as they develop, and plan for alternative and mitigating measures that it can ~~implement~~be implemented if needed.

Cash and Cash Equivalents

The Company considers all highly-liquid investments with an original maturity of three months or less when purchased to be cash equivalents. All cash and cash equivalents are held in ~~U.S.~~United States financial institutions. Cash and cash equivalents include money market funds that invest primarily in commercial paper and U.S. government and U.S. government agency obligations.

The Company maintains balances with financial institutions in excess of the Federal Deposit Insurance Corporation limit.

Trade Accounts Receivable and Allowances

Trade accounts receivable are amounts owed to the Company by its customers for product that has been delivered. The trade accounts receivable are recorded at the invoice amount, less prompt pay and other discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses represents the Company’s estimate of losses over the life of the receivables. The Company evaluates forward looking economic factors and uses professional judgment to determine the allowance for credit losses. The credit loss reserves are reviewed and adjusted periodically. Credit loss reserves were not material as of ~~September 30, 2022 or~~March 31, 2023 and December 31, ~~2021.~~2022.

Trade accounts receivable are aged based on the contractual payment terms. When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists.

Fair Value of Financial Instruments

~~Table of Contents~~

In accordance with Accounting Standards Codification (“ASC”) 825, Financial Instruments, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents (see Note 3) and the warrant liability (see Note 3) are carried at fair value. The warrant liability is measured at fair value ~~(see Note 3).~~in accordance with ASC 815.

Table of Contents

Other financial instruments, including accounts receivable, accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.

Inventory

Inventory is valued utilizing the weighted average costing method. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management’s current knowledge with respect to inventory levels, planned production and sales volume assumptions. As of March 31, 2023 and December 31, 2022, inventory reserves approximated $0.6 million.

Property and Equipment

Property and equipment, consisting of ~~manufacturing equipment,~~ office equipment and computer equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets.

Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to earnings in the period in which costs are incurred.

~~In the third quarter, the~~ Improvements and additions are capitalized in accordance with Company ~~transferred manufacturing equipment with a book value of $11.1~~ ~~million to Corium in exchange for relief from minimum material purchase requirements. The Company recorded a loss of~~ ~~$11.1 million for both the three and nine months ended September 30, 2022 on this disposition.~~policy.

Long-Lived Assets

In accordance with ASC 360, Property, Plant and Equipment, the Company’s policy is to review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. ~~At September 30, 2022, no indicators~~Management does not believe the carrying values of ~~impairment were present.~~any long-lived assets are impaired as of March 31, 2023.

Research and Development Expenses

Research and development ~~expenses consist~~costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel-related expenses, expenses related to manufacturing, clinical trial expenses, consulting fees, and support services used in ~~product~~drug development. All research and development costs are charged to operations as incurred in accordance with ASC 730, Research and Development.

In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received.

Advertising Costs

The Company has elected to expense advertising costs when incurred. Advertising costs totaled ~~$0.9 million~~zero and ~~$2.7~~$3.3 million for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021, respectively, and totaled $6.1 million and $8.8 million for the nine months ending September 30, 2022 and 2021,~~ respectively.

Deferred Financing Costs

Costs directly attributable to the Company’s senior secured term loan (see Note 7) are deferred and reported as a reduction of the related term loan. These costs represent ~~a 1% facility fee paid directly to the lender,~~ legal fees and other costs related to the term loan and are being amortized utilizing the straight-line method over the term of the loan. Amortization of deferred financing costs charged to interest expense was ~~$146,000~~$53,000 and ~~$69,000~~$73,000 for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021, respectively, and was $284,000 and $208,000 for the nine months ended September 30, 2022 and 2021,~~ respectively.

~~Table of Contents~~

Concentrations of Credit Risk

Financial instruments which potentially subject the Company to credit risk consist principally of cash, cash equivalents, ~~marketable securities~~ and accounts receivable. The Company invests its cash and cash equivalents ~~and marketable securities~~ in ~~debt instruments and~~ interest-bearing accounts in United States financial institutions, the balances of which exceed federally insured limits. The Company ~~has not recognized any losses from credit risks on such accounts. The Company~~ mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain

Table of Contents

liquidity, and have a high credit quality. The Company has not recognized any losses from credit risks on such accounts. The Company has no financial instruments with off balance sheet risk of accounting loss.

Major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three months ended ~~September 30, 2022,~~March 31, 2023, the Company had sales to ~~five~~four customers that individually accounted for more than 10% of its total revenue. These customers had sales of ~~$0.8~~$1.1 million, ~~$0.7~~$0.9 million, ~~$0.6 million, $0.5~~$0.8 million, and ~~$0.3~~$0.8 million, respectively, which represented ~~95%~~92% of total revenues in the quarter. In the ~~nine~~three months ended ~~September 30,~~March 31, 2022, the Company had sales to three customers that individually accounted for more than 10% of its total revenue. These customers had sales of $~~2.0~~0.6 million, ~~$1.8~~$0.5 million, and ~~$1.6~~$0.5 million, respectively,which represented ~~79%~~90% of total revenues ~~for~~in the ~~nine months ended September 30, 2022.~~quarter. Accounts receivable related to ~~the~~these ~~five~~four customers comprised ~~32%, 25%,~~ 24%, 8%26%, 28%, and ~~10%~~18%, respectively, as of ~~September 30, 2022.~~March 31, 2023.

Revenue Recognition

The Company recognizes revenue from the sale of its product, Twirla, in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606). The provisions of ASC 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

In accordance with ASC 606, the Company recognizes revenue at the point in time when its performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist primarily of wholesale distributors. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances as described in the Trade Accounts Receivable and Allowance policy.

The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when it is probable that a significant reversal will not occur in future periods. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue.

Twirla is sold to customers at the ~~Wholesale Acquisition Cost (WAC)~~wholesale acquisition cost (“WAC”). However, the Company records product revenue, net of reserves for applicable variable consideration. These types of variable consideration items reduce revenue and include the following:

•●

Distribution services fees;

•●

Prompt pay and other discounts;

•●

Product returns;

•●

Chargebacks;

•●

Rebates; and

•●

Co-payment assistance.

An estimate for each variable consideration item is made and is recorded in conjunction with the revenue being recognized. Generally, if the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these

~~Table of Contents~~

provisions are analyzed, and adjustments are made if necessary. Any adjustments made to these provisions would affect net product revenue and earnings in the current period.

In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company ~~relies~~relied on industry standard data and trend analysis assince historical sales data ~~for~~was not available as Twirla ~~are not yet available based on the~~was launched in December ~~2020 launch date. Once~~2020. As historical data becomes available, the Company will incorporate ~~Twirla specific~~that data into its estimates of variable consideration.

Table of Contents

The specific considerations that the Company uses ~~the following specific~~in estimating these amounts related to variable considerations ~~to estimate variable consideration.~~are as follows:

Distribution services fees – The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchase amount. The Company records these fees as contra trade accounts receivable on the balance sheet.

Prompt pay and other discounts – The Company incentivizes its customers to pay their invoices on time through prompt pay discounts. These discounts are an industry standard practice and the Company offers a prompt pay discount to each wholesale distributor customer. The specific prompt pay terms vary by customer and are contractually fixed. Prompt pay discounts are typically taken by the Company’s customers, so an estimate of the discount is recorded at the time of sale based on the WAC. Prompt pay discount estimates are recorded as contra trade accounts receivable on the balance sheet.

The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recorded.

Product returns – Customers have the right to return product that is within six months or less of the labeled expiration date or that is past the expiration date by no more than twelve months. Twirla was commercially launched in December 2020 and with limited historical sales data, an estimate for product returns as of ~~September 30, 2022~~March 31, 2023 was made based on ~~industry-standard~~industry standard data and trend analysis. ~~As time passes and historical data becomes available,~~Estimated product returns are recorded as other current liabilities in accrued expenses on the ~~Company will use historical sales and return data to estimate future product returns.~~balance sheet.

Chargebacks – Certain ~~government~~covered entities and ~~indirect customers (for example group purchasing organizations and 340B covered entities)~~government entities will be able to purchase the product at a price discounted below WAC. The difference between the ~~price paid by the~~ government or ~~other indirect purchaser~~covered entity purchase price and ~~the price paid by~~ the wholesale distributor purchase price of WAC will be charged back to the Company. The Company estimates the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra trade accounts receivable on the balance sheet.

Rebates – The Company will be subject to mandatory discount obligations under the Medicaid and Tricare programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Rebates are owed after the product has been dispensed to an end user and the Company has been invoiced. Rebates for Medicaid and Tricare are typically invoiced in arrears. The Company estimates the amount in rebates based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as other current liabilities in accrued expenses on the balance sheet.

Co-payment assistance -– The Company offers a co-payment assistance program to commercially insured patients whose insurance requires a co-payment to be made when filling their prescription. This is a voluntary program that is intended to provide financial assistance to patients meeting certain eligibility requirements. The Company estimates the amount of co-payment assistance based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Co-payment assistance estimates are recorded as other current liabilities in accrued expenses on the balance sheet.

~~Table of Contents~~

Provisions for the revenue reserves described above totaled ~~$3.2~~$4.5 million and ~~$0.6~~$1.2 million for the three months ending ~~September 30,~~March 31, 2023 and March 31, 2022, ~~and September 30, 2021, respectively, and $6.1 million and $0.9~~ ~~million for the nine months ending September 30, 2022 and 2021,~~ respectively. As of ~~September 30, 2022,~~March 31, 2023, reserves on the balance sheet associated with variable consideration were ~~$3.7~~$5.1 million.

Warrants

The Company accounts for its warrants to purchase common stock in accordance with ASC 480, Distinguishing Liabilities from Equity.

In connection with entering into a senior secured term loan facility in February 2020 (the “Perceptive Credit Agreement”), the Company issued warrants to purchase ~~35,000~~700 shares of its common ~~stock.~~ stock to the lender, Perceptive Credit Holdings III, L.P. (“Perceptive”). In connection with an amendment to that facility in February 2021, the

Table of Contents

Company issued ~~a warrant~~warrants to purchase ~~11,250~~225 shares of the Company’s common ~~stock.~~ ~~These warrant instruments~~stock (collectively, the “Perceptive Warrants”). The Perceptive Warrants qualify for equity classification and have been allocated based upon the relative fair value of the base instrument and the warrant. ~~These warrants~~The Perceptive Warrants are subject to repricing in the event of an offering of securities at a price lower than the existing strike price before ~~December 31, 2022.~~June 30, 2023. In March 2023, in connection with the Waiver and Sixth Amendment to the Perceptive Credit Agreement, the Company amended and restated the Perceptive Warrants to reset the strike price of the Perceptive Warrants. See ~~Note~~Notes 7 and 8 for additional information.

In connection with an underwritten public offering completed in October 2021, the Company issued warrants to purchase ~~333,333~~6,666 shares of its common stock. These warrants are classified as liabilities, were measured at fair value upon issuance, with subsequent changes in fair value reported in the Statement of Operations each reporting period. This offering also triggered an adjustment to the exercise price of the ~~existing warrants mentioned above,~~Perceptive Warrants, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. SeeSee Notes 7 and 8 for additional information.

In connection with a registered direct offering completed in March 2022, the Company issued warrants to purchase ~~1,242,813~~24,856 shares of its common stock. These warrants are classified as liabilities, were measured at fair value upon issuance, with subsequent changes in fair value reported in the Statement of Operations each reporting period. This offering also triggered an adjustment to the exercise price of the ~~existing warrants mentioned above,~~Perceptive Warrants, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. SeeSee Notes 7 and 8 for additional information.

In connection with a letter agreement and waiver entered into with an investor on April 2022, the Company issued warrants to purchase ~~212,188~~4,243 shares of common ~~stock, subject to adjustment thereunder.~~stock. These warrants are classified as liabilities, were measured at fair value upon issuance, with subsequent changes in fair value reported in the Statement of Operations each reporting period. See Note 8 for additional information.

In connection with a public offering completed in July 2022, the Company issued warrants to purchase ~~54,666,665~~1,093,333 shares of its common stock. T~~his~~These warrants are classified as liabilities, were measured at fair value upon issuance, with subsequent changes in fair value reported in the Statement of Operations each reporting period. This offering also triggered an adjustment to the exercise price of the ~~existing warrants in connection with the senior secured term loan facility mentioned above,~~Perceptive Warrants, which resulted in a reduction of the strike price for these warrants.

Income Taxes

The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and the tax basis of assets and liabilities, operating losses and tax credit carryforwards. Deferred income taxes are measured using the enacted tax rates and laws that are anticipated to be in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.

The Company has adopted the authoritative guidance on accounting for and disclosure of uncertainty in tax positions which prescribes a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The Company has no uncertain tax positions as of ~~September 30, 2022~~March 31, 2023 that qualify for either recognition or disclosure in the financial statements under this guidance.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation. The Company grants stock options for a fixed number of shares to employees and non-employees

~~Table of Contents~~

with an exercise price equal to no less than the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant-date fair value estimated using the weighted-average assumption of the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company elects to account for forfeitures when they occur. The

Table of Contents

equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.

The Company also awards restricted stock units (“RSUs”) to employees and its board of directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the ~~weighted-average~~weighted average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested RSUs and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented.

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for ~~both~~ the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ respectively, because to do so would be anti-dilutive (in common equivalent shares):


	September 30,		March 31,
	2022	2021	2023	2022
Common stock warrants	56,501,249	46,250	1,130,024	32,448
Unvested restricted stock units	7,125	6,342	129	131
Common stock options	278,854	258,808	7,889	6,120
Total	56,787,228	311,400	1,138,042	38,699

Recent Accounting Pronouncements

~~In May 2021,~~From time to time, new accounting pronouncements are issued by the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40): Issuer’sFinancial Accounting ~~for Certain Modifications~~Standards Board (“FASB”) or ~~Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). The guidance is effective for~~other standard setting bodies that the Company ~~on January 1, 2022. The~~adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of ~~this standard did not~~recently issued standards have or may have a material impact on its consolidated financial statements or disclosures.

The Company did not adopt any new accounting pronouncments during the three months ended March 31, 2023 that had a material effect on its financial statements.

3. Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

●

Level 1 — Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets consist of cash and cash equivalents. The Company has no Level 1 liabilities.

1817

Table of Contents

●

Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level 2 assets or liabilities.

●

Level 3 — Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participants price the fair value of the assets or liabilities. The Company has no Level 3 ~~assets or liabilities.~~assets. Level 3 liabilities consist of warrant liability.

The following table sets forth the Company’s financial instruments measured at fair value by level within the fair value hierarchy as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022 (in thousands):


	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
September 30, 2022
March 31, 2023
Assets:
Cash and cash equivalents	$	6,145	$	—	$	—	$	4,429	$	—	$	—
Total assets at fair value	$	6,145	$	—	$	—	$	4,429	$	—	$	—

Liabilities:
Warrant Liability							$	—	$	—	$	4,247
Total assets at fair value							$	—	$	—	$	4,247


	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
December 31, 2021
December 31, 2022
Assets:
Cash and cash equivalents	$	19,143	$	—	$	—	$	5,246	$	—	$	—
Total assets at fair value	$	19,143	$	—	$	—	$	5,246	$	—	$	—

Liabilities:
Warrant Liability							$	—	$	—	$	5,934
Total assets at fair value							$	—	$	—	$	5,934

The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants as of March 31, 2023 include (i) volatility 81.88% - 127.99%, (ii) risk-free interest rate 3.6% - 4.9%, (iii) strike price for the common warrants of $45 and $1,700, (iv) strike price for the preferred warrants $520, (v) fair value of common stock $11.20, and (vi) expected life 0.4 - 4.3 years. The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants as of December 31, 2022 include (i) volatility 136.8% - 137.4%, (ii) risk-free interest rate 4.2% - 4.7%, (iii) strike price for the common warrants $45.00 and $1,700, (iv) strike price for the preferred warrants of $520.00, (v) fair value of common stock $11.50, and (vi) expected life 0.7 - 4.5 years.

The following is a roll forward of the fair value of Level 3 warrants:


Beginning balance at December 31, 2022	$	5,934
Warrants issued		—
Change in fair value		(1,687)
Ending Balance March 31, 2023	$	4,247

There were no transfers between Level 1, 2 or 3 during ~~2022~~the three months ending March 31, 2023 or ~~2021.~~2022.

Table of Contents

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	September 30,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
Prepaid insurance	$	1,033	$	775	$	550	$	628
Other		2,801		1,508		593		775
Total prepaid expenses and other current assets	$	3,834	$	2,283	$	1,143	$	1,403

5. Accrued Liabilities

Accrued liabilities consist of the following (in thousands):


	September 30,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
Gross to net accruals					$	2,292	$	2,332
Accrued compensation	$	1,955	$	2,086		1,511		833
Accrued professional fees and other		3,197		1,477		2,507		743
Total accrued liabilities	$	5,152	$	3,563	$	6,310	$	3,908

6. Leases

The Company has no finance leases and one operating lease for its corporate headquarters in Princeton, NJ. The current lease commenced on December 1, 2021 and terminates on March 31, 2025. The lease provides the Company with an option to extend the lease for an additional five ~~years~~.years. Under the terms of the lease, the Company pays base annual rent subject to a fixed dollar amount increase each year, a fixed monthly charge for electricity, and other normal operating expenses such as taxes, repairs, and maintenance. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require variable lease payments, residual value guarantees, or restrictive covenants.

~~Table of Contents~~

The lease does not provide an implicit rate, therefore the Company used its incremental borrowing rate as the discount rate when measuring the operating lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease.

Operating lease expense was ~~$90,000~~$89,000 and ~~$38,000~~$89,000 for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021, respectively. Operating lease expense was $271,000 and $113,000~~ ~~for the nine months ended September 30, 2022 and 2021,~~ respectively. Operating cash flows used for operating leases during the three months ended ~~September 30,~~March 31, 2023 and 2022 were $77,000 and ~~2021 were~~ ~~$42,000 and $35,000,~~ ~~respectively. Operating cash flows used for operating leases during the nine months ended September 30, 2022 and 2021 were~~ ~~$132,000 and $102,000~~$21,000 respectively. As of ~~September 30, 2022,~~March 31, 2023, the ~~weighted-average~~weighted average remaining lease term was ~~2.50~~2.0 years and the weighted average discount rate was 11.8%.

Future minimum lease payments under non-cancellable leases as of ~~September 30, 2022~~March 31, 2023 were as follows (in thousands):

2022

$
66
2023

390
2024

398
2025

100
Total

$
954
Less: Interest

(127)
Present value of lease liability

$
827


2023	$	293
2024		397
2025		101
Total	$	791
Less: Interest		(83)
Present value of lease liability	$	708

7. Credit Agreement and Guaranty

On February 10, 2020, ~~(the “Closing Date”),~~ the Company entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings III, LP ~~a related party~~ (“Perceptive”), for a senior secured term loan credit facility of up to $35.0 million, (the “Perceptive

Table of Contents

Credit Agreement”). A first tranche of $5.0 million was funded on execution of the Perceptive Credit Agreement. A second tranche of $15.0 million was funded as a result of the approval of Twirla by the FDA. ~~On February 26, 2021 the Perceptive Credit Agreement was amended (the “Amended Perceptive Credit Agreement”) by creating a fourth~~Another $15.0 million tranche of ~~$10.0~~ ~~million that~~ was to be available to the Company based on the achievement of a revenue ~~milestone.~~milestone by December 31, 2021, which was not achieved. The other tranches of debt under the ~~Amended~~ Perceptive Credit Agreement are no longer available to the Company. On January 7, 2022, the Company prepaid $5.0 million of the outstanding debt, and Perceptive waived the prepayment premium. On July 8, 2022, the Company prepaid ~~$5.0~~$5.0 million of the outstanding debt, and Perceptive waived the prepayment premium. On July 25, 2022, the Company entered into a fifth amendment to the ~~Amended~~ Perceptive Credit Agreement, as amended (the “Fifth Amendment”). Pursuant to the Fifth Amendment, Perceptive agreed to release its security interest in certain assets being transferred from the Company to Corium in connection with an amendment to the Company’s Manufacturing and Commercialization Agreement with Corium and waive the Company’s obligations to comply with certain financial covenants through the end of 2022. In exchange, the Company agreed to prepay $7$7.0 million of outstanding principal under the ~~Amended~~ Perceptive Credit Agreement using the proceeds of recent sales under the Company’s ATM program with H.C. Wainwright & Co., ~~LLC.~~LLC (see Note 8). Such payment was made on July 25, 2022.

On March 21, 2023, the Company and Perceptive entered into a sixth amendment to the Perceptive Credit Agreement (the “Sixth Amendment”). The Sixth Amendment waived the Company’s obligations to (1) comply with certain financial covenants relating to minimum revenue requirements and minimum liquidity through June 30, 2023, and (2) file financial statements along with its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 that are not subject to any “going concern” qualification.

The facility will mature on February 10, 2024 ~~(the “Maturity~~(“Maturity Date”). Pursuant to the ~~Fifth Amendment,~~Perceptive Agreement, beginning August 31, 2022, the Company began making monthly principal payments in an amount equal to $75,000,, continuing until February 10, 2024, at which time all remaining principal amount outstanding is due.

Borrowings under the ~~Fifth Amendment~~Perceptive Credit Agreement will accrue interest at an annual rate equal to the London Interbank Offered Rate for one-month deposits (“LIBOR”) plus 10.25%, provided that LIBOR shall not be less than 1.5%. The rate of interest in effect as of ~~the Closing Date and at September 30, 2022~~March 31, 2023 was ~~11.75%~~14.92%. Upon the occurrence and during the continuance of any event of default under the ~~Fifth Amendment,~~Perceptive Credit Agreement, the interest rate automatically increases by 3.0% per annum.

The Company may prepay any outstanding loans in whole or in part. Any such prepayment of the loans is subject to a prepayment premium of ~~4.0% if such prepayment occurs after February 10, 2022 and on or prior to February 10, 2023; and~~ 2.0% ~~if such prepayment occurs after February 10, 2023 and prior to the Maturity Date.~~

~~Table of Contents~~

All of the Company’s obligations under the ~~Amended~~ Perceptive Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company’s tangible and intangible assets, including intellectual property.

The ~~Amended~~ Perceptive Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customary for similar financings. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the ~~Amended~~ Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company’s business activities; make certain investments or restricted payments (each as defined in the ~~Amended~~ Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company’s ability to make loan repayments under the ~~Amended~~ Perceptive Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ending ~~December 31, 2022,~~September 30, 2023, report revenues for the trailing 12-month period that exceed the amounts set forth in the ~~Amended Perceptive Credit Agreement,~~Sixth Amendment, which range from ~~$53.0~~$80.5 million for the fiscal quarter ending September 30, 2023 to $87.1 million for the fiscal quarter ending December 31, ~~2022~~2023. Pursuant to ~~$87.1~~ ~~million for~~ the ~~fiscal~~Sixth Amendment, the Company has received a waiver of certain financial covenants through the second quarter ~~ending December 31,~~of 2023. In the event the Company does not pay off the remainder of the outstanding principal under the facility, in the second quarter of 2023, the Company will need to negotiate for a waiver of its obligations to comply with ~~the covenants relating to revenues for Twirla in the first quarter of 2023.~~certain financial covenants.

In connection with the Perceptive Credit Agreement, the Company issued to Perceptive two warrants to purchase an aggregate of ~~35,000~~700 shares of the Company’s common stock (together, the “2020 Perceptive Warrants”). The first warrant is exercisable for ~~17,500~~350 shares of common stock at an exercise price of ~~$149.60~~$7,480 per share. The second warrant is exercisable for ~~17,500~~350 shares of common stock at an exercise price of ~~$186.80~~$9,340 per share. The 2020 Perceptive Warrants expire on February 10, 2027. In connection with the ~~Amended~~ Perceptive Credit Agreement, the Company issued to Perceptive a warrant to purchase ~~11,250~~225 shares of the Company’s common stock (the “2021 Perceptive Warrant” and,

Table of Contents

together with the 2020 Perceptive Warrants, the “Perceptive Warrants”) at an exercise price of ~~$114.80~~$5,740 per share. The 2021 Perceptive Warrant expires on February 26, 2028. The Perceptive Warrants contain anti-dilution provisions through June 30, 2023 and other warrant holder protections and are not exercisable to the extent that Perceptive would beneficially own more than 19.99% of the Company’s common stock as a result of the exercise. In connection with the Sixth Amendment, the Company amended and restated the Perceptive Warrants to reset the strike price of the Perceptive Warrants to $10.50 per warrant.

As a result of the public offering of the Company’s common stock completed in October 2021 (see Note 8), the ~~anti-dilution~~antidilution provision of the Perceptive Warrants was triggered, resulting in a reduction of the strike price for the Perceptive Warrants. Warrants to purchase ~~17,500~~350 shares of common stock that had an exercise price of ~~$186.80~~$9,340 per share were reduced to ~~$141.60~~$7,080 per share, warrants to purchase ~~17,500~~350 shares of common stock that had an exercise price of ~~$149.60~~$7,480 per share were reduced to ~~$115.20~~$5,760 per share, and warrants to purchase ~~11,250~~225 shares of common stock that had an exercise price of ~~$114.80~~$5,740 per share were reduced to ~~$90.80~~$4,540 per share.

As a result of the registered direct offering completed in March 2022 (see Note 8), the anti-dilution provision of the Perceptive Warrants was again triggered resulting in a further reduction of the strike price for the Perceptive Warrants. Warrants to purchase ~~17,500~~350 shares of common stock that had an adjusted exercise price of ~~$141.60~~$7,080 per share were reduced to ~~$105.52~~$5,276 per share, warrants to purchase ~~17,500~~350 shares of common stock that had an adjusted exercise price of ~~$115.20~~$5,760 per share were reduced to ~~$86.61~~$4,330.50 per share, and warrants to purchase ~~11,250~~225 shares of common stock that had an adjusted exercise price of ~~$90.80~~$4,540 per share were reduced to ~~$69.13~~$3,456.50 per share.

As a result of the public offering of the Company’s common stock completed in July 2022 (see Note 8), the ~~anti-dilution~~antidilution provision of the Perceptive Warrants was again triggered resulting in a reduction of the strike price for the Perceptive Warrants. Warrants to purchase ~~17,500~~350 shares of common stock that had an exercise price of ~~$105.52~~$5,276 per share were reduced to ~~$14.90~~$745 per share, warrants to purchase ~~17,500~~350 shares of common stock that had an exercise price of ~~$86.61~~$4,330.50 per share were reduced to ~~$12.37~~$618.50 per share, and warrants to purchase ~~11,250~~225 shares of common stock that had an exercise price of ~~$69.13~~$3,456.50 per share were reduced to ~~$10.03~~$501.50 per share.

The Company allocated the proceeds of ~~$20.0~~$20.0 million in accordance with ASC 470 based on the relative fair values of the debt and the Perceptive Warrants. The relative fair value of the Perceptive Warrants of approximately $3.6 million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the debt. The significant assumptions used in

~~Table of Contents~~

the preparing the option pricing model for valuing the Perceptive Warrants issued include (i) volatility (70.0%), (ii) risk free interest rate of 1.47% (estimated using treasury bonds with a 7-year life), (iii) strike prices of ~~$149.60~~$7,480 and ~~$186.80~~$9,340 for the common stock warrants, (iv) fair value of common stock ($~~160.40)~~8,020) and (v) expected life (7 years). The fair value of the 2021 Perceptive Warrants of approximately $1.1 million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the debt. The significant assumptions used in preparing the option pricing model for valuing the 2021 Perceptive Warrants issued include (i) volatility (103.5%), (ii) risk free interest rate of 1.15% (estimated using treasury bonds with a 7-year life), (iii) strike price of ~~$114.80~~$5,740 for the common stock warrant, (iv) fair value of common stock ($~~114.80)~~5,740) and (v) expected life (7 years). The fair value of the warrants as well as the debt issue costs incurred in connection with the entry into the Perceptive Credit Agreement, including a facility fee of 1% of the total amount of loans available under the facility, are presented as a direct deduction from the carrying amount of the term loan on the consolidated balance sheet as detailed below (in thousands).


	September 30,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
Notes payable	$	2,850	$	20,000	$	2,400	$	2,625
Debt issuance costs		(266)		(550)		(155)		(209)
Warrant discount		(1,266)		(2,617)		(737)		(990)
Total debt	$	1,318	$	16,833	$	1,508	$	1,426
Less, current portion		1,318		16,833		1,508		1,426
Long-term debt, less current portion	$	—	$	—	$	—	$	—

The fair value of the warrants and the debt issue costs are being amortized utilizing the effective interest method over the term of the loan. The Company recorded interest expense for the amortization of the fair value of the

Table of Contents

warrants and debt issue costs of $~~838,000~~307,000 and ~~$399,000~~$419,000 for the three months ended ~~September 30,~~March 31, 2023 and 2022, and 2021, respectively. The Company recorded interest expense for the amortization of the fair value of the warrants and debt issue costs of $1,635,000 and $1,132,000 for the nine months ended September 30, 2022 and 2021, respectively.

8. Stockholders’ ~~Equity~~Deficit

On January 7, 2022, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 150,000,000 shares to 300,000,000 shares.

~~On April 26, 2022,~~ the Company filed with the Secretary of State of the State of Delaware a certificate of amendment, or the Certificate of Amendment, to the Company’s Amended and Restated Certificate of Incorporation, which became effective on April 26, 2022. The ~~Certificate of Amendment implemented the Reverse Stock Split. On the effective date of April 26, 2022, the number of the Company’s issued and outstanding shares of common stock was decreased from~~ ~~146,741,862 to 3,668,546~~ ~~and the par value remained unchanged.~~ No fractional shares were issued as a result of the Reverse Stock Split. Stockholders who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all shares of the Company’s common stock outstanding immediately prior to the effective date of the Reverse Stock Split, as well as the number of shares ~~of common stock available~~authorized for issuance ~~under~~was not impacted by the ~~Company’s equity incentive plans. In addition,~~reverse stock splits implemented by the ~~Reverse Stock Split effected a reduction in the number of shares of common stock issuable upon the exercise of stock options, restricted stock units, or warrants outstanding.~~Company. See Note 11.

Shelf Registration Statement

On October 2, 2020, the Company filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate amount of $200.0 million (the “2020 Shelf Registration Statement”). On October 14, 2020, the 2020 Shelf Registration Statement was declared effective by the SEC. In the future, the Company may periodically offer one or more of these securities in amounts, prices, and terms to be announced when and if the securities are offered. At the time any of the securities covered by the 2020 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.

~~Table of Contents~~

Public Offerings

In October 2021, the Company completed a public offering of ~~666,666~~13,333 shares of its common stock and warrants to purchase ~~333,333~~6,666 shares of its common stock at a combined price of ~~$34.00~~$1,700 per share of common stock and one-half of a warrant to purchase one share of common stock. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses were approximately $21.1 million.

In July 2022, the Company completed a public offering of (1) ~~19,148,332~~382,966 shares of its common stock and warrants to purchase ~~38,296,664~~765,933 shares of its common stock at a combined price of ~~$0.90~~$45.00 per share of common stock and warrants and (2) ~~7,518,334~~150,366 pre-funded warrants to purchase ~~7,518,334~~150,366 shares of its common stock and warrants to purchase ~~15,036,668~~300,733 shares of its common stock at a combined price of ~~$0.8999~~$45.00 per share of common stock and pre-funded warrant. Proceeds from the public offering, net of underwriting discounts, commissions, and offering expenses were approximately $22.0 million.

ATM Sales Agreement

In March 2021, the Company entered into a common stock sales agreement (the ~~“2021 ATM~~“Sales Agreement”) under which the Company may sell up to an aggregate of $50.0 million in gross proceeds through the sale of shares of common stock from time to time in “at-the-market” equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). The Company agreed to pay a commission of up to 3% of the gross proceeds of any common stock sold under the ~~2021 ATM~~Sales Agreement. During the year ended December 31, 2021, the Company issued and sold ~~172,879~~3,457 shares of common stock under the ~~2021 ATM~~Sales Agreement resulting in net proceeds to the Company of approximately $9.3 million.

On January 10, 2022, the Company filed a prospectus supplement to its 2020 Shelf Registration Statement registering an at-the-market offering program (the ~~“January 2022~~“2022 ATM”) the Company entered into for the sale of up to $50.0 million of shares of its common stock. The Company agreed to pay a commission of up to 3% of the gross proceeds of any common stock sold under the ~~January 2022 ATM.~~Sales Agreement. During the ~~nine~~three months ended ~~September 30,~~March 31, 2022, the Company issued and sold ~~25,623~~512 shares of common stock under the ~~January 2022 ATM~~Sales Agreement resulting in net proceeds to the Company of approximately $0.3 million. On April 26, 2022, the Company terminated the ~~January~~ 2022 ATM.

On April 27, 2022, the Company entered into a new at-the-market offering program ~~(“April~~(the “April 2022 ~~ATM”~~ATM Agreement”) with H.C. Wainwright LLC and Co. (the “Sales Agent”), under which the Company ~~may,~~is authorized to sell up to an aggregate of $12.8 million in gross proceeds through the sale of shares of common stock from time to ~~time in its sole discretion, issue and sell through or to the Sales Agent, acting as the Company’s agent, up to $12,841,000 of shares of the Company’s common stock (the “Placement Shares”).~~time. The Company agreed to pay ~~the Sales Agent~~ a commission of up to 3.0% of the gross ~~sales~~ proceeds of any ~~Placement Shares~~common stock sold under the April 2022 ~~ATM.~~ATM Agreement. Through September 30, 2022, the Company issued and sold a total of ~~8,687,502~~173,750 shares of common stock under the April 2022 ATM Agreement, representing the entire capacity of the

Table of Contents

April 2022 ATM, resulting in net proceeds of approximately $12.2 million. On August 22, 2022, the Company increased the April 2022 ATM (“August 2022 ATM”). As increased, the Company ~~may now~~was eligible to offer and sell, from time to time through the Sales Agent, shares of ~~the Company’s~~its common stock having an aggregate offering price of up to~~$75.0~~ $75.0 million.

During the year ended December 31, 2022, the Company issued and sold 78,852 shares of common stock under the August 2022 ATM resulting in net proceeds of approximately $0.9 million. During the three months ending March 31, 2023, the Company issued and sold 72,698 shares for net proceeds of approximately $1.0 million. On April 12, 2023, the Company filed a prospectus supplement to its registration statement on Form S-3 for the August 2022 ATM verifying that it is now eligible to sell up to $4.5 million worth of shares through its ATM.

Registered Direct Offering

On March 14, 2022, the Company filed a prospectus supplement to its 2020 Shelf Registration Statement registering a direct offering (the “2022 Preferred Stock Offering”) of 2,425 shares of Series A convertible preferred stock (the “Series A Preferred Stock”) and 2,425 shares of Series B convertible preferred stock (the “Series B Preferred Stock”) and Series A warrants (the “Series A Warrants”) to purchase up to an aggregate of ~~606,250~~12,125 shares of the common stock of the Company and Series B warrants (the “Series B Warrants”) to purchase up to an aggregate of ~~606,250~~12,125 shares of common ~~Stock.~~stock. Each share of Series A Preferred Stock and Series B Preferred Stock has a stated value of $1,000 per share and a conversion price of ~~$8.00~~$400.00 per share. The shares of preferred stock issued in the 2022 Preferred Stock Offering are convertible into an aggregate of ~~606,250~~12,125 shares of common stock. The Series A Warrants have an exercise price of ~~$10.40~~$520.00 per share, will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The Series B Warrants have an exercise price of ~~$10.40~~$520.00 per share, will become exercisable six months following the date of issuance, and will expire one and one-half years following the initial exercise date. Proceeds from the 2022 Preferred Stock Offering, net of the placement

~~Table of Contents~~

agent’s fees and offering expenses were approximately $4.1 million. A portion of the ~~placement agent’s~~placement’s agents fees included warrants to purchase ~~30,313~~606 shares of the common stock of the Company at a strike price of ~~$10.00~~$500.00 per share. The warrants become exercisable six months following the date of issuance and will expire 5 years following the commencement of sales in the 2022 Preferred Stock Offering.

The Company allocated the net proceeds of $4.1 million in accordance with ASC 470 based on the relative fair values of the preferred stock and the Series A Warrants and Series B Warrants (collectively, the “Warrants”). The relative fair value of the Warrants of approximately $2.1 million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the preferred stock. The significant assumptions used in preparing the option pricing model for valuing the Warrants issued include (i) volatility of 111.9% for the Series A warrants and 69.7% for the Series B Warrants, (ii) risk free interest rate of 2.1% for the Series A Warrants and 1.6% for the Series B Warrants, (iii) strike price of $10.40, (iv) fair value of common stock ($9.48) and (v) expected life of 5.5 years for the Series A Warrants and 1.5 years for the Series B Warrants.

On March 15, 2022, 2,425 shares of the Series A Preferred Stock were converted into ~~303,125~~6,025 shares of the Company’s common stock. On April 4, 2022, 2,425 shares of the Series B Preferred Stock were converted into ~~303,125~~6,025 shares of the Company’s common stock.

On April 25, 2022, the Company entered into a letter agreement and waiver (the “Letter Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice”), pursuant to which Armistice consented to the Company entering into and effecting an at-the-market (“ATM”) offering facility. On March 14, 2022, the Company entered into the 2022 Preferred Stock Offering with Armistice, under which agreement, the Company was restricted from entering into and effecting an ATM offering facility until the 180-day anniversary of the Closing Date. Pursuant to the Letter Agreement, the Company issued to ~~Armisitice~~Armistice a new common stock purchase warrant (“New Warrant”), on the same terms and conditions as the Series A Warrants, provided that such New Warrant shall be exercisable into ~~212,188~~4,243 warrant ~~shares, subject to adjustment thereunder.~~shares. The Series A Warrants have an exercise price of ~~$10.40~~$520 per share, and will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The New Warrant is exercisable 6 months after the date of the Letter Agreement.

On July 6, 2022, the Company completed a best efforts public offering (the “Offering”) in which the Company raised net proceeds of $22.0 million through the sale of 382,966 shares of common stock and 150,366 pre-funded warrants (“Series B pre-funded warrants”) to purchase 150,366 shares of common stock. Both the sales of shares of common stock and pre-funded warrants were accompanied by Series A-1 and Series A-2 warrants (together the “Series A warrants”) to purchase shares of common stock. The Series A-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire thirteen months from the date of issuance. H.C. Wainwright acted as the exclusive placement agent in connection with the Offering and, as compensation, received a cash fee of 7% of the aggregate proceeds raised in the Offering. The Company also issued to certain designees of H.C. Wainwright warrants to purchase up to 26,666 shares of common stock with an exercise price of $56.25 per share.

Table of Contents

Stock-Based Compensation Expense

Stock-based compensation expense was allocated as follows (in thousands):

Three Months Ended

Nine Months Ended

September 30,

September 30,


2022

2021

2022

2021

Cost of goods sold

$
29

$
84

$
104

$
219

Research and development

90

134

284

362

Selling and marketing

40

31

120

109

General and administrative

377

638

1,461

1,782

Total

$
536

$
887

$
1,969

$
2,472


	Three Months Ended
	March 31,
	2023		2022
Cost of goods sold	$	29	$	44
Research and development		87		103
Selling and marketing		31		40
General and administrative		351		577
Total	$	498	$	764

9. Income Taxes

Sale of New Jersey Net Operating Losses

The Company has participated in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by The New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused NOLs and unused research and development credits to sell these tax benefits for at least 80% of the value of the tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. The Program is administered by The New Jersey Economic Development Authority and the New Jersey Department of the Treasury’s Division of Taxation. The Company had previously reached the maximum lifetime benefit of $15.0 million under the historical ~~Program,~~Program; however, in January 2021 the Program was amended to extend the maximum lifetime benefit to $20.0 million. The Company received final approval in March 2022 for ~~$4.7~~$4.7 million of additional cash benefit that was received in April 2022.

~~Table of Contents~~

10. Commitments and Contingencies

The Company has several firm purchase commitments, primarily related to the manufacture and supply of Twirla and the supply of a field force of sales representatives to provide certain detailing services, sales operation services, compliance services, and training services. Future firm purchase commitments under these agreements, the last of which ends in 2033, total ~~$239.1~~ $236.1 million. This amount does not represent all of the Company’s anticipated purchases in the future, but instead represents only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on non-cancelable minimum spend in ~~2021~~2023 or termination amounts. Additionally, the Company purchases products and services as needed with no firm commitment.

In April 2020, the Company entered into a manufacturing and commercialization agreement with Corium ~~Inc.,~~ (the “Corium Agreement”). Under the Corium Agreement, the Company has a requirement to order quarterly minimum volumes of approximately ~~$5.6~~$5.6 million of product. In the event that the Company does not order the minimum volume, the Company is required to pay an additional fee equal to twenty-five percent (~~25%~~(25%) per unit of the transfer price for all units ordered in that quarter. The Company did not meet the minimum volume order in the first or second quarter of 2022, and has, therefore, paid the additional 25% per unit fee as a penalty for all units ordered during the period. Based on current demand expectations for Twirla, the Company did not expect to meet the minimum volume order for the balance of 2022 and would be subject to the additional fee on future purchases. On July 25, 2022 the Company and Corium entered into Amendment No. 1 to the Corium Agreement (the “Amendment”) that is designed to restructure the contract minimums applicable to the purchase of manufactured Twirla and other services provided by Corium, transfer equipment ownership to Corium to support the manufacture of Twirla, and extend the term of the Corium Agreement. Pursuant to the Amendment, the parties agreed to adjust the process for the Company providing Corium certain binding and non-binding forecasts required under the Corium Agreement. Additionally, Corium will not enforce the original quantity minimums in the Corium Agreement, which are waived and replaced by new minimums that are based on Corium’s revenue for product purchased by the Company, expiring raw materials, and other services billed by Corium to support batch production and release. The guaranteed minimum revenue requirement for ~~2022 is~~ ~~$5.3 million, for~~ 2023 is $7.0 million, and is $22.5 million for 2024 and each year thereafter. In the event that the Company does not meet the guaranteed minimum revenue requirements in any given year, the Company will be required to make additional payments to Corium for the shortfall. The Company agreed to make certain monthly supplemental payments to Corium through December 2023, which payments are eligible to be retroactively reduced based upon product orders placed by the Company during ~~2022 and~~ 2023 meeting certain designated

Table of Contents

thresholds. In connection with the supplemental payments, Corium will retain the proceeds for the sale of certain raw materials to which the Company would otherwise have economic right to offset such supplemental payments. Further, the Company agreed to reimburse Corium for any unused raw materials in the event the Company’s actual product requirements are lower than initially forecasted. Pursuant to the Amendment, the term of the Corium Agreement was extended to December 31, 2033. Pursuant to the Amendment, the parties agreed to transfer ownership of certain manufacturing equipment used in the manufacture of Twirla from the Company to Corium under a Bill of Sale dated July 25, 2022.

The Company records a provision for contingent losses when it is both probable that a liability has been incurred, and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial position. As of ~~September 30, 2022,~~March 31, 2023, the Company has not recorded a provision for any contingent losses.

11. Subsequent Events

On April 10, 2023, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment, or the Certificate of Amendment, to the Company’s Amended and Restated Certificate of Incorporation, which became effective on April 10, 2023. The Certificate of Amendment implemented a 1-for-50 reverse stock split of the Company’s common stock. On the effective date of April 10, 2023, the number of the Company’s issued and outstanding shares of common stock was decreased from 46,605,134 to 932,101, and the par value remained unchanged. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective date of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split effected a reduction in the number of shares of common stock issuable upon the exercise of stock options, restricted stock units, or warrants outstanding.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following information should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (the “SEC”) on March ~~30, 2022.~~23, 2023. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part 1, Item 1A, “Risk Factors” of our Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Dollars in the text and in tabular format are presented in thousands, except per share data, or as otherwise indicated.

~~Table of Contents~~

Overview

We are a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. We are committed to innovating in women’s healthcare where there continues to be unmet needs – not only in contraception – but also in other meaningful women’s health therapeutic areas.

~~Our~~ We are focused on our advancement as a commercial company and the growth of our first and only product, Twirla, a once-weekly prescription combination hormonal contraceptive patch.

Twirla, which was approved in February 2020 and launched in early December 2020, is a once-weekly prescription combination hormonal contraceptive patch. It exposes patients to an estrogen dose consistent with commonly prescribed combined hormonal contraceptives, or CHCs, and is lower than the estrogen dose found in other marketed contraceptive patches. We believe there is a market need for a contraceptive patch that is designed to deliver hormonal exposure equivalent to 30 mcg of estrogen and 120 mcg of progestin in a convenient once-weekly dosage form that may support compliance in a noninvasive fashion. Twirla leverages our proprietary transdermal patch technology called Skinfusion^®. Skinfusion is designed to allow drug delivery through the skin while promoting patch adhesion and patient comfort and wearability, which may help support compliance.

~~With the approval of Twirla we~~We are ~~now~~ focused on our advancement as a commercial company. During ~~2022,~~2023, we plan to continue implementing our commercialization plan for Twirla, with the goal of ~~becoming~~establishing a growing position in the hormonal contraceptive ~~market leader, and ultimately,~~market. In addition to growing Twirla, we also plan to continue pursuing opportunities to broaden our portfolio to address areas of unmet medical need in women’s health.

Our Strategy

Our near-term goal is to establish ~~an initial~~a growing franchise in the multi-billion dollar U.S. hormonal contraceptive market built on approval of Twirla in the ~~U.S.~~United States. Our resources are currently focused on the commercialization of Twirla. We also expect to ~~explore~~continue exploring possible expansion through business development activities, such as acquiring access to new products through in-licensing, co-promotion or other collaborative arrangements.

Our current priorities are as follows:

●

Continue to manage our available cash and obtain financing to fund our business plan without delay;

●

Continue to implement our commercialization plans for Twirla to increase uptake of Twirla in the United States, through targeted digital direct to consumer advertising, ~~including Connected TV (“CTV”) advertising in key markets,~~ growing our telemedicine presence through new partnerships and our existing partnership with Nurx^®, and driving growth in the non-retail ~~channel;~~channel through our collaboration with Afaxys, which provides us access to some of the largest Planned Parenthood organizations in the country;

●

Continue to expand access to Twirla through multiple business channels including ~~third-party payor contracts,~~ retail and specialty pharmacies, telemedicine, ~~and~~ government contracting, and non-retail channels, including public health ~~centers;~~centers through our relationship with Afaxys;

●

~~Reduce our operating loss and continue to progress towards generating positive cash flows;~~

Table of Contents

●

Expand coverage and reimbursement for Twirla in the United States from private and public third-party payors;

●

Maintain and manage the supply chain for Twirla to support increased commercialization of Twirla across the United States and working through existing and future inventory prior to product becoming short-dated;

●

~~Continue~~Reduce our operating loss and continue to ~~manage our available~~progress towards generating positive cash ~~and obtain financing to fund our business plan without delay;~~flows;

●

Evaluate the advancement of our existing pipeline and its possible expansion through business development activities; and

●

Continue to implement our obligations related to our post-marketing commitment and the post-marketing requirement studies of Twirla.

It should be noted that ~~current~~the possibility of continued public health threats could adversely affect our ongoing or planned business operations. ~~In particular,~~For example, the ~~ongoing COVID-19~~coronavirus (“COVID-19”) pandemic ~~has~~previously resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public

~~Table of Contents~~

gatherings, and stay at home orders. The most significant impacts to our business were encountered by sales representatives promoting Twirla in the field, as some offices limited opportunities for face-to-face interactions with healthcare providers. ~~In many cases~~Re-implementation of COVID-19 ~~restrictions have recently eased, but re-implementation of such~~ restrictions, if necessary in the future, may disrupt our business and/or could adversely affect our commercialization plans and results. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including personnel at third-party manufacturing facilities and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on us. While to date we have been able to continue to execute our overall business plan, some of our business activities slowed and took longer to complete as we adjusted to the challenges of operating in a largely remote setting with our employees. While we have acclimated to a hybrid work model with our employees, anotherAnother shut down necessitating work in a completely remote environment could result in delays to our business activities and commercialization plan. ~~Overall, we recognize the challenges of commercializing a new product in a pandemic,~~We will continue to closely monitor events as they develop, and plan for alternative and mitigating measures that we can implement if needed.

Financial Overview

Since our inception in 1997 we have devoted substantial resources to developing and seeking regulatory approval for Twirla, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. While we anticipate that a portion of our operating expenses will continue to be related to research and development as we pursue our post-marketing studies for Twirla, including planning our long-term, prospective observational safety study, which is a post marketing requirement from the FDA, and evaluate the development of our pipeline, our operating expenses have substantially shifted towards commercialization activities for Twirla. As of September 30,through 2022, we generated minimal revenue and have ~~significantly reduced~~never been profitable. Through March 31, 2023, we had an accumulated deficit of $414.1 million, and our ~~operating expenses through a number of measures, including optimizing our sales force, reducing reliance on third-party service providers, targeting our advertising spend,~~net loss was $5.4 million and ~~reorganizing our executive leadership team~~$10.4 million for the three months ended March 31, 2023 and ~~general personnel.~~2022, respectively. We ~~are committed~~expect to continue to ~~look~~incur significant operating losses for ~~ways to reduce expenses and focus efforts and resources on commercialization and uptake of~~the foreseeable future as we commercialize Twirla.

We have ~~funded~~financed our operations primarily through ~~sales~~the public offerings of ~~common stock,~~equity securities, convertible preferred stock, ~~convertible promissory notes~~term loans and ~~term loans.~~sale of our New Jersey net operating losses. As of ~~September 30, 2022, and December~~March 31, ~~2021,~~2023, we had ~~$6.1 million and $19.1~~$4.4 million in cash and cash ~~equivalents, respectively.~~

On February 10, 2020, we entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings III, LP, a related party (“Perceptive”), for a senior secured term loan credit facility of up to $35.0 million (the “Perceptive Credit Agreement”). A first tranche of $5.0 million was funded on execution of the Perceptive Credit Agreement. A second tranche of $15.0 million was funded as a result of the approval of Twirla by the FDA. On February 26, 2021 the Perceptive Credit Agreement was amended (the “Amended Perceptive Credit Agreement”) by creating a fourth tranche of $10.0 million that was to be available based on the achievement of a revenue milestone. The other tranches of debt under the Amended Perceptive Credit Facility are no longer available to us. In connection with the Amended Perceptive Credit Agreement, the Company issued to Perceptive a warrant to purchase 11,250 shares of the Company’s common stock with an exercise price of $10.03 per share. equivalents.

~~On January 7, 2022, we prepaid $5.0 million of the outstanding debt, and Perceptive waived the prepayment premium.~~ ~~On July 8, 2022, we prepaid $5.0 million of the outstanding debt, and~~ ~~Perceptive waived the prepayment premium~~. On July 25, 2022, we entered into a fifth amendment to the Amended Perceptive Credit Agreement, as amended (the “Fifth Amendment”). Pursuant to the Fifth Amendment, Perceptive agreed to release its security interest in certain assets being transferred from the Company to Corium in connection with ~~an amendment to the Company’s Manufacturing and Commercialization Agreement with Corium and waive our obligations to comply with certain financial covenants through the end of 2022~~. In exchange, we agreed to prepay $7 million of outstanding principal under the Amended Perceptive Credit Agreement using the proceeds of recent sales under our ATM program with H.C. Wainwright & Co., LLC. Such payment was made on July 25, 2022, and Perceptive waived the prepayment premium. Pursuant to the Fifth Amendment, beginning August 31, 2022, we began making monthly principal payments in an amount equal to $75,000 continuing until February 10, 2024, at which time all remaining principal amount outstanding is due.

~~Table of Contents~~

In March 2021, we entered into a common stock sales agreement (the “2021 ATM Agreement”) under which we are authorized to sell up to an aggregate of $50.0 million in gross proceeds through the sale of shares of common stock from time to time in “at-the-market” equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). We agreed to pay a commission of up to 3% of the gross proceeds of any common stock sold under this agreement. During the year ended December 31, 2021, we issued and sold a total of 172,879 shares of common stock under the 2021 ATM Agreement resulting in net proceeds of approximately $9.3 million.

In October 2021, we completed a public offering of 666,666 shares of our common stock and warrants to purchase 333,333 shares of our common stock at a combined price of $34.00 per share of common stock and one-half of a warrant to purchase one share of common stock. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses were approximately $21.1 million.

In January 2022, we entered into a common stock sales agreement (the “January 2022 ATM”) under which we are authorized to sell up to an aggregate of $50.0 million in gross proceeds through the sale of shares of common stock from time to time in “at-the-market” equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). We agreed to pay a commission of up to 3% of the gross proceeds of any common stock sold under this agreement. During the nine months ended September 30, 2022 we issued and sold a total of 25,623 shares of common stock under the January 2022 ATM resulting in net proceeds of approximately $0.3 million. On April 26, 2022, we terminated the January 2022 ATM.

~~On March 13, 2022, we entered into a~~ Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused institutional investor (the “Purchaser”), pursuant to which the Company issued, in a registered direct offering (the “2022 Preferred Stock Offering”), 2,425 shares of Series A convertible preferred stock (the “Series A Preferred Stock”) and 2,425 shares of Series B convertible preferred stock (the “Series B Preferred Stock”) and Series A warrants (the “Series A Warrants”) to purchase up to an aggregate of 606,250 shares of the common stock of the Company and Series B warrants (the “Series B Warrants”) to purchase up to an aggregate of 606,250 shares of common stock. Each share of Series A Preferred Stock and Series B Preferred Stock has a stated value of $1,000 per share and a conversion price of $8.00 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 606,250 shares of common stock. The Series A Warrants have an exercise price of $10.40 per share, will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The Series B Warrants have an exercise price of $10.40 per share, will become exercisable six months following the date of issuance, and will expire one and one-half years following the initial exercise date. The Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties. Total gross proceeds from the 2022 Preferred Stock Offering, before deducting the placement agent's fees and other estimated offering expenses, are $4.9 million. The 2022 Preferred Stock Offering closed on March 14, 2022.

On April 25, 2022, we entered into a letter agreement and waiver (the “Letter Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice”), pursuant to which Armistice consented to us entering into and effecting an at-the-market (“ATM”) offering facility. Pursuant to the Letter Agreement, we issued to Armisitice a new common stock purchase warrant (“New Warrant”), on the same terms and conditions as the Series A Warrants, provided that such New Warrant shall be exercisable into 212,188 warrant shares, subject to adjustment thereunder. The Series A Warrants have an exercise price of $10.40 per share, and will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date.

On April 27, 2022, we entered into a new at-the-market offering program (the “April 2022 ATM”) with H.C. Wainwright LLC, and Co. (the “Sales Agent”) under which we were authorized to sell up to an aggregate of $12,841,000 in gross proceeds through the sale of shares of common stock from time to time in “at the market” equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). We agreed to pay a commission of up to 3% of the gross proceeds of any common stock sold under this agreement. Through September 30, 2022, we issued and sold a total of 8,687,502 shares of common stock under the April 2022 ATM, representing the entire capacity of the April 2022 ATM, resulting in net proceeds of approximately $12.2 million. On August 22, 2022, the we increased the April 2022 ATM (“August 2022 ATM”). As increased, we may now offer and sell shares of the Company’s common stock having an aggregate offering price of up to$75.0 million.

On July 6, 2022, we completed a best efforts public offering (the “Offering”) in which we raised net proceeds of $22.0 million through the sale of 19,148,332 shares of common stock and 7,518,334 pre-funded warrants (“Series B pre-funded warrants”) to purchase 7,518,334 shares of common stock. Both the sales of shares of common stock and

~~Table of Contents~~

pre-funded warrants were accompanied by Series A-1 and Series A-2 warrants (together the “Series A warrants”) to purchase shares of common stock. The Series A-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire thirteen months from the date of issuance. H.C. Wainwright acted as the exclusive placement agent in connection with the Offering and, as compensation, received a cash fee of 7% of the aggregate proceeds raised in the Offering. We also issued to certain designees of H.C. Wainwright warrants to purchase up to 1,333,333 shares of commons stock with an exercise price of $1.125 per share.

Moving forward, we plan to continue to monitor our cash and cash equivalents balances, in an effort to ensure we have adequate liquidity to fund our operations. If ~~the COVID-19 pandemic or other~~we encounter unforeseen factors that impact our current business plan or our ability to generate revenue from the ~~launch~~commercialization of Twirla, we believe we have the ability to revise our commercial plans, including curtailing sales and marketing spending, to allow us to continue to fund our ~~operations.~~operations using existing cash and cash equivalents.

As we develop as a commercial company, we anticipate that our operating expenses will be primarily focused on commercialization activities for Twirla. We ~~have generated minimal revenue and have never been profitable for any year. Our net loss was $74.9 million, $51.9 million and $18.6 million for~~also expect a portion of our operating expenses in the ~~years ended December~~ 31, 2021, 2020 and 2019, respectively. Our net loss was $20.0 million and $16.8 million for the three months ended September 30, 2022 and 2021, respectively. Our net loss was $43.6 million and $51.5 million for the nine months ended September 30, 2022 and 2021, respectively. We expectfuture will be related to continue to incur significant operating losses for the foreseeable future as we commercialize Twirla. This includes commercially launching Twirla, advancing our other potential product candidates and expanding our research and development ~~programs.~~as we conduct our long-term, prospective observational safety study for Twirla, which is a post marketing requirement from the FDA, and evaluate the development of our pipeline. As of March 31, 2023, we have significantly reduced our operating expenses through several measures, including optimizing our sales force, reducing reliance on third-party service providers, reducing our advertising spend, and reorganizing our executive leadership team and general personnel. We are committed to continuing to explore ways to reduce expenses and focus efforts and resources on commercialization and uptake of Twirla. Our ability to reduce our operating loss and begin to generate positive cash flow from operations depends on the continued success in commercializing Twirla and maintaining discipline over our operating expenses. We continue to explore business development opportunities to commercialize a second product, and to do so in a way that we believe would

Table of Contents

contribute to our ability to reduce our operating losses and reduce our time to achieving positive cash flow from operations.

Going Concern

As of ~~September 30, 2022,~~March 31, 2023, we had cash and cash equivalents of ~~$6.1~~$4.4 million. We ~~believe~~closely monitor our cash and cash equivalents and expect that our current cash will support operations through ~~December 31, 2022~~June 2023..

We have generated losses since inception, used substantial cash in operations, and anticipate we will continue to incur net losses for the foreseeable future. Our future success depends on our ability to obtain additional capital and/or implement various strategic alternatives, and there can be no assurance that any financing can be realized by us, or if realized, what the terms of any such financing may be, or that any amount that we are able to raise will be adequate. If we are unable to ~~obtain funds~~raise capital when needed or on acceptable terms, we then will be unable to continue the commercialization of Twirla, ~~and~~ be required to cut operating costs, and forego future development and other opportunities. Based upon the foregoing, management has concluded that there is substantial doubt about our ability to continue as a going concern through the 12 months following the date on which this Quarterly Report on Form 10-Q is filed.

We continue to analyze various alternatives, including refinancing alternatives, potential asset sales, and mergers and acquisitions. We cannot be certain that these initiatives or raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to raise funds, whether through the issuance of equity or convertible debt securities, or any combination thereof, these securities may have rights, preferences, or privileges senior to those of our common stock, and our current stockholders will experience dilution. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, including Twirla, or grant licenses on terms that may not be favorable to us. If we are unable to obtain funds when needed or on acceptable terms, we then may be unable to continue the commercialization of Twirla and may also be required to further cut operating costs, forego future development and other opportunities, and may need to seek bankruptcy protection.

The unaudited financial statements as of ~~September 30, 2022~~March 31, 2023 have been prepared under the assumption that we will continue as a going concern for the next 12 months. Our ability to continue as a going concern is dependent upon our uncertain ability to obtain additional capital, reduce expenditures, and/or execute on our business plan and continue the commercial growth of Twirla. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We do not own any manufacturing facilities and rely on our contract manufacturer, Corium, for all aspects of the manufacturing of Twirla. We will need to continue to invest in the manufacturing process for Twirla, and incur significant expenses, in order to be capable of supplying projected commercial quantities of Twirla. We have incurred significant expenses in order to create an infrastructure to support the commercialization of Twirla, including sales, marketing, distribution, medical affairs, and compliance functions. We will need to generate significant revenue to achieve profitability, and we may never do so.

Financial Operations Overview

Revenue

To date, we have generated minimal revenue from product sales. In the future, in addition to revenue from product sales, we may generate revenue from license fees, milestone payments or royalties from the sale of products developed using our intellectual property. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize Twirla and any product candidates that we may advance in the future. If we fail to successfully commercialize Twirla, or any other product candidates we advance in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, could be adversely affected.

2928

Table of Contents

For the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ net sales totaled ~~$3.1~~$3.8 million and ~~$1.3~~$1.8 million, respectively, representing the sale of ~~33,282~~43,446 units and ~~10,650~~16,818 units, respectively. For the nine months ended September 30, 2022 and 2021, net sales totaled $7.0 million and $2.6 million, respectively, representing the sale of 71,652 units and 20,976 units, respectively. The increase in net sales was driven by increased sales in both the retail and non-retail channel through our collaboration with Afaxys.

Cost of Product Revenues

Cost of product revenues include direct and indirect costs related to the manufacturing of Twirla sold, including packaging services, freight, obsolescence, and allocation of overhead costs that are primarily fixed such as depreciation, salaries and benefits, and insurance. We expect these relatively fixed costs to become less significant as a percentage of sales with anticipated volume increases. There was no direct cost of product revenue on approximately 3,000 units sold in the nine months ended September 30, 2021, as those units were validation inventory which was previously expensed as research and development expense in the fourth quarter of 2020.

For the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ cost of product revenues totaled ~~$1.4~~$2.0 million and ~~$2.7~~$1.5 million, respectively. ~~For the nine months ended September 30, 2022 and 2021, cost of product revenues totaled $5.2 million and $5.0 million, respectively.~~

Research and Development Expenses

Since our inception and through approval of Twirla by the FDA in February 2020, we focused our resources on our research and development activities. Research and development expenses consist primarily of costs incurred for the development of Twirla and other current and future potential product candidates, and include:

●

expenses incurred under agreements with contract research organizations, or CROs, and investigative sites that conduct our clinical trials and preclinical studies;

●

employee-related expenses, including salaries, benefits, travel and stock-based compensation expenses;

●

the cost of acquiring, developing, and manufacturing clinical trial materials, including the supply of our potential product candidates; and

●

costs associated with research, development, and regulatory activities.

Research and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to us by our third-party vendors.

~~Research~~Historically, research and development activities ~~are~~were central to our business model and to date, our research and development expenses have been related primarily to the development of Twirla. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We do not currently utilize a formal time allocation system to capture expenses on a project-by-project basis, as the majority of our past and planned expenses have been and will be in support of Twirla. Our research and development expenses have reduced significantly over the past three years.

For the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ our research and development expenses were approximately $0.8 million and ~~$1.6~~$1.3 million, respectively. ~~For the nine months ended September 30, 2022 and 2021, our research and development expenses were approximately $2.9 million and $4.6 million, respectively~~ The following table summarizes our research and development expenses by functional area.

Three Months Ended

Nine Months Ended

September 30,

September 30,

(In thousands)

(In thousands)


2022

2021

2022

2021

Clinical development

$
115

$
1,011

$
917

$
2,496
Regulatory

107

36

366

174
Personnel related

476

397

1,334

1,592

~~Table of Contents~~

Manufacturing—commercialization		—		15		—		(56)

									Three Months Ended
									March 31,
									(In thousands)
									2023		2022

Clinical development									$	45	$	448
Regulatory										111		133
Personnel related										520		573
Stock-based compensation		90		134		284		362		87		103
Total research and development expenses	$	788	$	1,593	$	2,901	$	4,568	$	763	$	1,257

It is difficult to determine with any certainty the exact duration and completion costs of any of our future clinical trials of Twirla or our current and future potential product candidates we may advance. It is also difficult to

Table of Contents

determine if, when, or to what extent we will generate revenue from the commercialization and sale of Twirla or our potential product candidates that obtain regulatory approval.

Future research and development costs incurred for our potential product candidates and required post-marketing studies will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, the rate of subject enrollment, access to additional capital, and significant and changing government regulation. For the foreseeable future, we expect the current public health crisis to have a negative effect on the conduct of clinical trials. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the ~~FDA~~U.S. Food and Drug Administration (“FDA”) or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, or experience issues with our manufacturing capabilities, we could be required to expend significant additional financial resources and time with respect to the development of that product candidate. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, coupled with an assessment of each product candidate’s commercial potential. Substantially all of our resources are currently dedicated to ~~commercializing~~continuing to commercialize Twirla.

Selling and Marketing Expenses

Selling and marketing expenses consist principally of the cost of salaries and related costs for personnel in sales and marketing, our contract sales force, brand building, advocacy, market research and consulting. Selling and marketing expenses are expensed as incurred.

For the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ our selling and marketing expenses totaled approximately ~~$5.6~~$4.7 million and ~~$9.4~~ ~~million, respectively. For the nine months ended September 30, 2022 and 2021, our selling and marketing expenses totaled approximately $23.5 million and $30.3~~$10.6 million, respectively. Our commercial launch of Twirla in the United States utilized a contract sales force. We anticipate that our selling and marketing expenses will continue to be significant as our commercialization efforts continue.

General and Administrative Expenses

General and administrative expenses consist principally of salaries and related costs for personnel in executive, finance and administrative functions including payroll taxes and health insurance, stock-based compensation and travel expenses. Other general and administrative expenses include facility-related costs, insurance and professional fees for legal, patent review, consulting, and accounting services. General and administrative expenses are expensed as incurred.

For the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ our general and administrative expenses totaled approximately ~~$2.8~~$3.1 million and ~~$3.4 million, respectively. For the nine months ended September 30, 2022 and 2021, our general and administrative expenses totaled approximately $9.8 million and $11.4~~$4.0 million, respectively. We anticipate that our general and administrative expenses will stabilize in the future.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and related disclosures. On an ongoing basis, our actual results may differ significantly from our estimates.

~~Table of Contents~~

There have been no material changes to our critical accounting policies and estimates from the information discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K, as filed with the SEC on March ~~30, 2022.~~23, 2023.

3230

Table of Contents

Results of Operations

Comparison of the Three Months Ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~


	Three Months Ended						Three Months Ended
	September 30,						March 31,
	(In thousands)						(In thousands)
	2022		2021		Change		2023		2022		Change

Revenues, net	$	3,002	$	1,287	$	1,715	$	3,813	$	1,761	$	2,052
Cost of product revenues		1,425		2,711		(1,286)		2,003		1,527		476
Gross profit		1,577		(1,424)		3,001		1,810		234		1,576

Operating expenses:
Research and development	$	788	$	1,593	$	(805)	$	763	$	1,257	$	(494)
Selling and marketing		5,560		9,386		(3,826)		4,670		10,553		(5,883)
General and administrative		2,815		3,371		(556)		3,085		3,997		(912)
Loss on disposition of assets		11,122		—		11,122
Total operating expenses		20,285		14,350		5,935		8,518		15,807		(7,289)
Loss from operations	$	(18,708)	$	(15,774)		(2,934)	$	(6,708)	$	(15,573)		8,865

Other income (expense)
Interest income		46		1		45		33		1		32
Interest expense		(1,004)		(999)		(5)		(402)		(872)		470
Unrealized gain on warrant liability								1,687		1,384		303
Total other income (expense), net		(958)		(998)		40		1,318		513		805
Loss before benefit from income taxes		(19,666)		(16,772)		(2,894)		(5,390)		(15,060)		9,670
Benefit from income taxes		—		—		—		—		4,675		(4,675)
Net loss	$	(19,666)	$	(16,772)	$	(2,894)	$	(5,390)	$	(10,385)	$	4,995

Revenues. ~~Revenues,~~Revenue, net increased by ~~$1.7~~$2.1 million or ~~133%~~117% from ~~$1.3~~$1.8 million for the three months ended ~~September 30, 2021~~March 31, 2022 to ~~$3.0~~$3.8 million for the three months ended ~~September 30,~~March 31, 2023. Unit sales increased by approximately 26,000 units, or 258%, from 16,818 units for the three months ended March 31, 2022,. to 43,446 units for the three months ended March 31, 2023. The decrease in the percentage of growth between dollars and units pertains to increased price discounts offered to the non-retail sales channel. Revenue, net consists of sales of Twirla which was approved by the FDA in February 2020 and launched in the US in December 2020, and reflects the shipment of Twirla to specialty distributors, net of estimates for applicable variable consideration, which consist primarily of wholesale distribution fees, prompt pay and other discounts, rebates, chargebacks, product returns and co-pay assistance programs.

~~Cost of product revenues.~~ Cost of product revenues totaled $1.4 million and consist of direct and indirect costs related to the manufacturing of Twirla sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs that are primarily fixed such as depreciation, salaries and benefits, and insurance. Cost of product revenues in the prior period included $1.4 million of obsolescence reserves for inventory not expected to be sold prior to its shelf life date.

~~Research and development expenses.Research and development expenses decreased by $0.8 million, or 51%, from $1.6 million for the three months ended September 30, 2021 to $0.8 million for the three months ended September 30, 2022.~~ This decrease in research and development expenses was primarily due to a decrease in clinical development expenses of $0.9 million for the three months ended September 30, 2022 as compared to the three months ended September 30, 2021. ~~This decrease reflects a reduction in spending related to our pipeline evaluation and development.~~

~~Selling and marketing expenses.~~ Selling and marketing expenses decreased by $3.8 million, or 41%, from $9.4 million for the three months ended September 30, 2021 to $5.6 million for the three months ended September 30, 2022. This decrease in selling and marketing expenses is due to reduced spending on marketing initiatives and the optimization of our contract sales force.

~~General and administrative expenses.~~ General and administrative expenses decreased by $0.6 million, or 16%, from $3.4 million for the three months ended September 30, 2021 to $2.8 million for the three months ended September 30, 2022. This decrease in general and administrative expense was primarily due to reduced headcount.

~~Table of Contents~~

~~Loss on disposition of assets.~~ ~~In accordance with ASC 610-20, we recognized an $11.1 million one-time, non-cash charge, which represents the loss on the transferof fixed assets to Corium in connection with the amended Corium agreement (see Note 10 to the financial statements).~~

~~Interest income.~~ ~~Interest income comprises interest earned on cash and cash equivalents.~~

~~Interest expense.~~ Interest expense is attributable to our term loan with Perceptive and includes the amortization of the discount associated with allocating value to the common stock warrants issued to Perceptive and the amortization of the deferred financing costs associated with the term loan. Interest expense was flat at $1.0 million for both the three months ended September 30, 2022 and September 30, 2021 as higher non-cash interest amortization of the fair value of the warrants and debt issue costs offset lower cash interest due to principal payments made on the term loan.

~~Comparison of the Nine Months Ended September 30, 2022 and 2021~~

Nine Months Ended



September 30,

(In thousands)

2022

2021

Change

Revenues, net

$
6,888

$
2,587

$
4,301
Cost of product revenues

5,183

5,017

166
Gross profit

1,705

(2,430)

4,135

Operating expenses:






Research and development

$
2,901

$
4,568

$
(1,667)
Selling and marketing

23,523

30,263

(6,740)
General and administrative

9,837

11,386

(1,549)
Loss on disposition of assets

11,122

—

11,122
Total operating expenses

47,383

46,217

1,166
Loss from operations

$
(45,678)

$
(48,647)

2,969

Other income (expense)






Interest income

50

24

26
Interest expense

(2,699)

(2,914)

215
Total other income (expense), net

(2,649)

(2,890)

241
Loss before benefit from income taxes

(48,327)

(51,537)

3,210
Benefit from income taxes

4,675

—

4,675
Net loss

$
(43,652)

$
(51,537)

$
7,885

~~Revenues.~~ Revenues, net increased by $4.3 million or 166% from $2.6 million for the nine months ended September 30, 2021 to $6.9 million for the nine months ended September 30, 2022. Revenue, net consists of sales of Twirla, which was approved by the FDA in February 2020 and launched in the US in December 2020, and reflects the shipment of Twirla to specialty distributors, net of estimates for applicable variable consideration, which consist primarily of wholesale distribution fees, prompt pay and other discounts, rebates, chargebacks, product returns, and co-pay assistance programs.

Cost of product revenues. Cost of product revenues ~~totaled $5.2~~increased by $0.5 million or 33% from $1.5 million for the three months ended March 31, 2022 to $2.0 million for the three months ended March 31, 2023, and ~~consist~~consists of direct and indirect costs related to the manufacturing of Twirla sold, including third-party manufacturing costs, packaging services, freight, and ~~allocation~~allocations of overhead costs that are primarily fixed such as ~~depreciation,~~ salaries, ~~and~~ benefits, and insurance. Additional costs incurred in the nine months ending September 30, 2022 include $0.7 million of supplemental payments and expired raw materials payments to Corium as agreed to under the amended Corium agreement. Additional costs incurred in the nine months ending September 30, 2021 include $1.4 million obsolescence reserves for inventory not expected to be sold prior to its shelf life date.

~~Table of Contents~~

Research and development expenses. Research and development expenses decreased by ~~$1.7~~$0.5 million, or ~~36%~~39%, from ~~$4.6~~$1.3 million for the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 to ~~$2.9~~$0.8 million for the ~~nine~~three months ended ~~September 30, 2022.~~March 31, 2023. This decrease in research and development expenses was primarily due to a decrease in clinical development expenses of ~~$1.6~~$0.4 million for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 as compared to the ~~nine~~three months ended ~~September 30, 2021.~~March 31, 2022. This decrease reflects a reduction in spending related to our pipeline evaluation and development.

Table of Contents

Selling and marketing expenses. Selling and marketing expenses decreased by ~~$6.7~~$5.9 million, or ~~22%~~56%, from ~~$30.3~~$10.6 million for the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 to ~~$23.5~~$4.7 million for the ~~nine~~three months ended ~~September 30, 2022.~~March 31, 2023. This decrease in selling and marketing expenses is due to reduced spending on marketing initiatives and the optimization of our contract sales force.

General and administrative expenses. General and administrative expenses decreased by ~~$1.5~~$0.9 million, or ~~14%~~23%, from ~~$11.4~~$4.0 million for the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 to ~~$9.8~~$3.1 million for the ~~nine~~three months ended ~~September 30, 2022.~~March 31, 2023. This decrease in general and administrative expense was primarily due to ~~the previously announced forfeiture of senior management bonuses for 2021and reduced headcount, partially offset by higher professional fees.~~

~~Loss on disposition of assets.~~ ~~In accordance with ASC 610-20, we recognized an $11.1 million one-time, non-cash charge, which represents the loss on the transferof fixed assets~~lower personnel related costs due to ~~Corium in connection with the amended Corium agreement (see Note 10 to the financial statements).~~lower headcount.

Interest income. Interest income comprises interest earned on cash and cash equivalents.

Interest expense. Interest expense is attributable to our term loan with Perceptive and includes the amortization of the discount associated with allocating value to the common stock warrants issued to Perceptive and the amortization of the deferred financing costs associated with the term loan. Interest expense decreased by ~~$215,000~~$0.5 million for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 compared to the ~~nine~~three months ended ~~September 30, 2021 as higher~~March 31, 2022 due to the reduction in the principal amount outstanding on the loan.

Unrealized gain on warrant liability. Unrealized gain on warrant liability reflects the non-cash ~~interest amortization of~~changes in the estimated fair value of the ~~warrants and debt issue costs offset lower cash interest due to principal payments made on the term loan.~~warrant liability.

Benefit from income taxes. Benefit from income taxes ~~reflects~~represents $4.7 million received under the State of New Jersey’s Technology Business Tax Certificate Transfer Program ~~(the “Program”)~~ sponsored by The New Jersey Economic Development ~~Authority. The Program enables approved biotechnology companies with unused NOLs and unused research and development credits to sell these tax benefits for at least 80% of~~Authority during the value of the tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. The Program is administered by The New Jersey Economic Development Authority and the New Jersey Department of the Treasury’s Division of Taxation. We have reached the maximum lifetime benefit $20.0 million.three months ending March 31, 2022.

Liquidity and Capital Resources

At ~~September 30, 2022,~~March 31, 2023, we had cash and cash equivalents totaling ~~$6.1~~$4.4 million. We invest our cash equivalents in short-term highly liquid, interest-bearing investment-grade and government securities in order to preserve principal.

The following table sets forth the primary sources and uses of cash for the periods indicated:

Nine Months Ended September 30,

(In thousands)


2022

2021


Net cash used in operating activities

$
(34,388)

$
(48,584)

Net cash (used in) provided by investing activities

(133)

39,515

Net cash provided by financing activities

21,523

9,341

Net (decrease) increase in cash and cash equivalents

$
(12,998)

$
272

~~Table of Contents~~


	Three Months Ended March 31,
	(In thousands)
	2023		2022

Net cash used in operating activities	$	(1,595)	$	(14,751)
Net cash used in investing activities		—		(126)
Net cash provided by (used in) financing activities		778		(523)
Net decrease in cash and cash equivalents	$	(817)	$	(15,400)

Operating Activities

We incurred significant costs in the area of research and development, including CRO fees, manufacturing, regulatory and other clinical trial costs, as Twirla was being developed. With the approval of Twirla early in 2020, our operating expenses shifted substantially to selling and marketing as we built out our commercial infrastructure. Net cash used in operating activities was ~~$34.4~~$1.6 million for the ~~nine~~three months ended ~~September 30,~~March 31, 2023 and consisted primarily of a net loss of $5.4 million and a $1.7 million unrealized gain on warrants, offset by non-cash stock-based compensation expense of $0.5 million, $0.4 million of other non-cash charges, primarily interest expense, and $4.6 million of positive working capital changes, primarily an increase in accounts payable and accrued expenses. Net cash used in operating activities was $14.8 million for the three months ended March 31, 2022 and consisted primarily of a net loss of ~~$43.6~~$10.4 million, a $1.4 million unrealized gain on warrants and ~~negative working capital changes of $7.0~~a $4.7 million increase in income taxes receivable, offset by non-cash stock-based compensation expense of ~~$2.0~~$0.8 million, depreciation expense of $1.3 million, a $11.1 million non-cash loss on the disposition of fixed assets, and $1.8 million of other non-cash charges, primarily interest expense. Net cash used in operating activities was $48.6 million for the nine months ended September 30, 2021 and consisted primarily of a net loss of $51.5$0.5 million, and $3.8 million in negative working capital changes, offset by a non-cash inventory reserve of $1.4 million, non-cash stock-based compensation expense of $2.5 million, depreciation expense of $1.5 million, and $1.4$0.5 million of other non-cash charges, primarily interest expense.

Investing Activities

Net cash used in investing activities for the ~~nine~~three months ended ~~September 30,~~March 31, 2022 was $0.1 million and consisted of acquisitions of equipment. ~~Net cash provided by~~There were no investing activities ~~for~~during the ~~nine~~three months ended ~~September 30, 2021 was $39.5 million and primarily represents net sales and maturities~~March 31, 2023.

Table of ~~marketable securities.~~Contents

Financing Activities

Net cash provided by financing activities for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 was ~~$21.5~~$0.8 million, which consists of net proceeds of $1.0 million from the sale of 72,699 shares of our common stock through an at-the-market, or ATM, sales program partially offset by $0.2 million of principal payments on our debt. Net cash used in financing activities for the three months ended March 31, 2022 was $0.5 million, which consists of a principal payment of long-term debt of $5.0 million, offset by net proceeds of $4.1 million from the sale of preferred stock in a registered direct offering ~~net proceeds of $22.0 million from the sale 26,666,666 shares of our common stock in a public offering,~~ and proceeds of ~~$12.6~~$0.3 million from the sale of ~~8,713,125~~20,498 shares of our common stock through an ~~at-the-market, or~~ ATM sales program, partially offset by a principal payment of short-term debt of $17.0 million. Net cash provided by financing activities for the nine months ended September 30, 2021 was $9.3 million, which consists of net proceeds of $9.3 million from the sale of 6,915,151 shares of our common stock under the 2021 ATM Agreement, and stock option proceeds of $0.1 million.program.

Funding Requirements and Other Liquidity Matters

We closely monitor our cash and cash equivalents balances, in an effort to ensure we have adequate liquidity to fund the operations of the Company. If ~~the COVID-19 pandemic or other~~unforeseen factors impact our current business plan or our ability to generate revenue from the ~~launch~~commercialization of Twirla, we believe we have the ability to revise our commercial plans, including curtailing sales and marketing spending, to allow us to continue to fund our operations. In addition, on October 2, 2020 we filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate amount of $200.0 million (the “2020 Shelf Registration Statement”). On October 14, 2020, the 2020 Shelf Registration Statement was declared effective by the SEC. In the future, we may periodically offer one or more of these securities in amounts, at prices, and on terms to be announced when and if the securities are offered. At any time any of the securities covered by the 2020 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.

On ~~March 18, 2021,~~January 10, 2022, we filed a prospectus supplement to our 2020 Shelf Registration Statement registering ~~an at-the-market offering program~~the 2022 ATM we entered into for the sale of up to $50.0 million of shares of our common stock. During the ~~year ended December 31, 2021, we sold 172,879 shares of our common stock under the at-the-market program resulting in net proceeds of approximately $9.3 million.~~

On October 8, 2021, we filed a prospectus supplement to our 2020 Shelf Registration Statement registering a public offering of 666,666 shares of common stock sold together with warrants to purchase up to 333,333 shares of our common stock at a combined offering price of $34.00 per share of common stock and one-half of a warrant to purchase one share of common stock. The warrants have an exercise price of $340.00 per share, are exercisable immediately, and will expire five years from the date of issuance. On October 13, 2021, we completed the offering and realized proceeds of approximately $21.1 million, net of underwriting discounts, commissions and offering expenses.

~~Table of Contents~~

~~On January 10, 2022, we filed a prospectus supplement to our 2020 Shelf Registration Statement registering the January 2022 ATM. During the nine~~three months ending ~~September 30,~~March 31, 2022, we sold and issued ~~25,623~~512 shares of common stock resulting in net proceeds of $0.3 ~~million under the January 2022 ATM.~~million. On April, 26, 2022, we terminated the ~~January~~ 2022 ~~ATM.~~ATM Agreement.

On March 13, 2022, we entered into ~~the 2022~~a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused institutional investor (the “Purchaser”), pursuant to which we issued, in a registered direct offering (the “2022 Preferred Stock ~~Offering.~~Offering”), 2,425 shares of Series A convertible preferred stock (the “Series A Preferred Stock”) and 2,425 shares of Series B convertible preferred stock (the “Series B Preferred Stock”) and Series A warrants (the “Series A Warrants”) to purchase up to an aggregate of 12,125 shares of the common stock of the Company (the “Common Stock”) and Series B warrants (the “Series B Warrants”) to purchase up to an aggregate of 12,125 shares of Common Stock. Each share of Series A Preferred Stock and Series B Preferred Stock has a stated value of $1,000 per share and a conversion price of $400.00 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 12,125 shares of Common Stock. The Series A Warrants have an exercise price of $520 per share, will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The Series B Warrants have an exercise price of $520 per share, will become exercisable six months following the date of issuance, and will expire one and one-half years following the initial exercise date. The Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties. The 2022 Preferred Stock Offering closed on March 14, 2022 and total net proceeds were approximately ~~$4.1~~$4.3 million.

On April 25, 2022, we entered into a Letter Agreement with the Purchasers, pursuant to which the Purchasers consented to us entering into and effecting an ATM offering facility. Pursuant to the Letter Agreement, we issued to the Purchasers the New Warrant, on the same terms and conditions as the Series A Warrants, provided that such New Warrant shall be exercisable into 4,243 warrant shares, subject to adjustment thereunder. The Series A Warrants have an exercise price of $520 per share, will become exercisable six months after the date of the Letter Agreement, and will expire 5 years following the initial exercise date.

On April 27, 2022, we entered into the April 2022 ATM Agreement under which we are authorized to sell up to an aggregate of $12.8 million in gross proceeds through the sale of shares of common stock from time to time in the April 2022 ATM. We agreed to pay a commission of up to 3% of the gross proceeds of any common stock sold under this agreement. Through September 30, 2022, we issued and sold a total of ~~8,687,502~~173,750 shares of common stock under the April 2022 ATM Agreement, representing the entire capacity of the April 2022 ATM, resulting in net proceeds of approximately $12.2 million. On August 22, 2022, we increased the April 2022 ATM (“August 2022 ATM”). As increased, we ~~may now~~were eligible to offer and sell, from time to time through the Sales Agent, shares of ~~the Company’s~~our common stock having an aggregate offering price of up ~~to$75.0~~to $75.0 million. During the year ended December 31, 2022,

Table of Contents

we issued and sold 78,852 shares of common stock under the August 2022 ATM resulting in net proceeds to us of approximately $0.9 million. During the three months ending March 31, 2023, we issued and sold 72,699 shares resulting in proceeds of approximately $1.0 million. On April 12, 2023, we filed a prospectus supplement to our registration statement on Form S-3 for the August 2022 ATM verifying that we are now eligible to sell up to $4.5 million worth of shares through our ATM.

On July 6, 2022, we completed a best-efforts public offering (the “Offering”) in which we raised net proceeds of $22.0 million through the ~~Offering.~~sale of 382,966 shares of common stock and 150,366 pre-funded warrants (“Series B pre-funded warrants”) to purchase 150,366 shares of common stock. Both the sales of shares of common stock and pre-funded warrants were accompanied by Series A-1 and Series A-2 warrants (together the “Series A warrants”) to purchase shares of common stock. The Series A-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire thirteen months from the date of issuance. H.C. Wainwright acted as the exclusive placement agent in connection with the Offering and, as compensation, received a cash fee of 7% of the aggregate ~~procees~~proceeds raised in the Offering. We also issued to certain designees of H.C. Wainwright warrants to purchase up to ~~1,333,333~~26,666 shares of ~~common~~commons stock with an exercise price of ~~$1.125~~$56.25 per share. ~~Proceeds from the Offering, net of placement agent fees and offering expenses were approximately $22.0 million~~.

We believe we may have the potential to access additional capital through the 2022 ATM, selling additional debt or equity securities or obtaining a line of credit or other loan as required.

We expect to continue to incur significant operating expenses for the foreseeable future in connection with our ongoing activities as we:

maintain a sales and marketing infrastructure and contract manufacturing arrangement to support the continued commercialization of Twirla in the United States;

•

continue to commercialize Twirla and seek increased uptake of Twirla in the United States;

•

continue to evaluate additional line extensions for Twirla and initiate development of potential product candidates in addition to Twirla;

maintain, leverage and expand our intellectual property portfolio; and

maintain operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts.

We may also need to raise additional funds if we need to change components of our commercial plan or if we encounter any unforeseen events that affect our current business plan, or we may choose to raise additional funds to provide us with additional working capital. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital when needed or on attractive terms or are unable to enter into strategic collaborations, we then may be unable to successfully commercialize Twirla and may also be required to further cut operating costs, forego future development and other opportunities or even terminate our operations, which may involve seeking bankruptcy protection. Because of the numerous risks and uncertainties associated with such developments, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the commercialization of Twirla. Our future capital requirements will depend on many factors, including:

the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for Twirla;

•

the revenue received from commercial sales of Twirla;

•

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and

•

the costs associated with any potential business or product acquisitions, strategic collaborations, licensing agreements or other arrangements that we may establish.

Table of Contents

We do not have any committed external source of funds. Until such time, if ever, as we can generate substantial cash flows from product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements.

Contractual Obligations and Commitments

In April 2020, we entered into a Manufacturing and Commercialization agreement with Corium, Inc., which we refer to as the Corium Agreement, and which replaced our previous development agreement. Pursuant to the Corium Agreement, Corium will manufacture and supply all of our product requirements for Twirla at certain specified rates. Under the terms of the Corium Agreement, Corium is to be the exclusive supplier of Twirla for ten years. The Corium Agreement included a quarterly minimum purchase commitment and a fixed price per unit for two years from December 2020, the date of the first commercial batch purchase order invoice, depending on annual purchase volume. During 2021, we did not meet all of our minimum quantity purchases from Corium, and as a result, paid penalties as required by our agreement with Corium. On July 25, 2022 we, along with Corium, amended the Corium Agreement to restructure the minimums applicable to the purchase of manufactured Twirla and to extend the term of the Corium Agreement until December 31, 2033. The Corium Agreement terminates automatically on December 31, 2033, but may be terminated for any reason upon the written mutual agreement of both parties; provided, however, that the parties must confer in good faith regarding possible mutual termination. In the event of such termination, we may still effect purchase orders after the notice of termination is given and until the time any such termination becomes effective. As of ~~September 30, 2022,~~March 31, 2023, the minimum amount committed totals ~~$234.7~~$231.7 million.

In April 2020, we entered into a project agreement with inVentiv Commercial Services, LLC, or inVentiv, a Syneos Health Group Company, which we refer to as the Syneos Agreement, under our Master Services Agreement with inVentiv. Pursuant to the Syneos Agreement, inVentiv, through its affiliate Syneos Selling Solutions, will provide a field force of sales representatives to provide certain detailing services, sales operation services,

~~Table of Contents~~

compliance services, and training services with respect to Twirla to us in exchange for an up-front implementation fee and a fixed monthly fee. Effective February 1, 2022, we entered into an amendment to the Syneos Agreement that extended the term until August 23, 2024. At that time, the Syneos Agreement will terminate automatically unless extended upon the mutual written agreement of the Parties. We may terminate the Syneos Agreement for any reason upon timely written notice without incurring a termination fee. As of ~~September 30, 2022,~~March 31, 2023, the minimum amount committed totals ~~$3.4~~$3.5 million.

Our operating lease commitment relates to our lease of office space in Princeton, New Jersey. The lease for this space commenced in December 2021, and the minimum payments over the remaining ~~33 month~~24-month term totals ~~$1.0~~$0.8 million as of ~~September 30, 2022.~~March 31, 2023.

Recent Accounting Pronouncements

See Note 2 to our financial statements that discusses new accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk

We are exposed to market risks in the ordinary course of our business. Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, financing, exchange rates or other factors. These market risks are principally limited to interest rate fluctuations.

We had cash and cash equivalents of ~~$6.1~~$4.4 million and ~~$19.1~~$5.2 million at ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively, consisting primarily of funds in cash and money market accounts. The primary objective of our investment activities is to preserve principal and liquidity while maximizing income without significantly increasing risk. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of our investment portfolio, we do not believe an immediate 10.0% increase in interest rates would have a material effect on the fair market value of our portfolio, and accordingly we do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates.

Our results of operations and cash flows are subject to fluctuations due to changes in interest rates. We do not believe that we are materially exposed to changes in interest rates. We do not currently use interest rate derivative

Table of Contents

instruments to manage exposure to interest rate changes. We estimate that a 1% unfavorable change in interest rates would not have a material effect on interest expense for the ~~nine~~three months ended ~~September 30, 2022.~~March 31, 2023.

Inflation Risk

Inflation generally affects us by increasing our cost of labor and pricing of contracts and agreements. We do not believe that inflation had a material effect on our business, financial condition, or results of operations during the three months ended ~~September 30, 2022.~~March 31, 2023.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including

~~Table of Contents~~

our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, due to the material weakness in our internal control over financial reporting described below.

Management has concluded that there is a material weakness in the review procedures related to complex securities including the determination of liability versus equity treatment of certain warrants. Management has concluded that there is a material weakness in the design and operating effectiveness of the Company’s review procedures related to complex securities. The reviewer had insufficient resources supporting the assessment of the complex securities accounting model and the review procedures were not performed at a level of precision to prevent or detect a material misstatement on a timely basis in the normal course of the review. Based on this assessment, management believes that our internal control over financial reporting was not effective as of December 31, 2022.

Changes to Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, ~~the Company’s~~our internal control over financial reporting.

Remediation Plan for Material Weakness

Management has actively initiated remediation efforts to address the material weakness. Specifically, we expanded and improved our review process for complex securities and related accounting standards. We plan to further improve this process by enhancing access to accounting literature and identification of third-party accounting professionals with whom to consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

Table of Contents

Part II: Other Information

Item 1. Legal Proceedings.

We are not currently subject to any material legal proceedings.

Item 1A. Risk Factors.

The following ~~updated~~ risk factor should be considered in addition to our risk factors previously reported in our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~

~~Risks Related to Ownership of Our Common Stock~~

2022.

We are not in compliance with the Nasdaq continued listing requirements. If we are unable to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock could be delisted, which could affect our common stock's market price and liquidity and reduce our ability to raise capital.

On ~~August 15, 2022,~~March 27, 2023, we received a deficiency letter from ~~the~~ Nasdaq ~~Stock Market, or Nasdaq, indicating~~notifying us that we ~~have failed to comply~~are not in compliance with the minimum ~~bid price~~stockholders’ equity requirement ~~which~~for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires ~~that~~ companies listed on the Nasdaq Capital Market to maintain ~~a minimum bid price~~stockholders’ equity of at least ~~$1.00 per share~~$2,500,000 (the ~~“Bid Price~~“Stockholders’ Equity Requirement”). ~~The notification~~Our Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022 reported stockholders’ equity of ~~noncompliance had no immediate effect~~$(5,545,000), which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. As of the date of this filing, the Company does not have a market value of listed securities of $35 million, or net income from continued operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years, the alternative quantitative standards for continued listing ~~of our common stock.~~

on the Nasdaq Capital Market. In accordance with Nasdaq rules, we ~~have a 180-calendar day grace period,~~were provided 45 calendar days from the receipt of the Nasdaq notification, or until ~~February 13,~~May 11, 2023, to submit a plan to regain compliance (the “Compliance ~~Date”~~Plan”),. We submitted that plan on May 11, 2023. If the Compliance Plan is acceptable to Nasdaq, they may grant an extension of 180 calendar days from the date of the Nasdaq notification to regain compliance with the ~~Bid Price~~Stockholders’ Equity Requirement. The continued listing standard would have been met if our common stock had a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-calendar day grace period.

If ~~we do~~Nasdaq does not ~~regain compliance with the Bid Price Requirement by~~accept the Compliance Date, Nasdaq may grant an additional 180 calendar day compliance period, if we meet the continued listing requirement for value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market and provide written notice of our intention to cure the deficiency during the second 180 calendar day compliance period by effecting a reverse stock split, if necessary.

~~If we do not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq,~~Plan, Nasdaq will provide ~~notice~~us with written notification that ~~our common stock will be subject to delisting.~~the Compliance Plan has been rejected. At that time, we may appeal the ~~Nasdaq staff's~~Staff’s determination to a Nasdaq Hearings Panel.

We intend to monitor ~~the closing bid price of~~ our ~~common stock~~stockholders’ equity and, if appropriate, consider ~~our~~further available options to ~~resolve the noncompliance~~regain compliance with the ~~Bid Price~~Stockholders’ Equity Requirement. There can be no assurance that we will ~~be able to~~ regain compliance ~~with the Bid Price Requirement~~ or ~~will~~ otherwise ~~be in~~maintain compliance with any of the other ~~Nasdaq~~ listing ~~criteria.~~ requirements.

If our securities are delisted, it could be more difficult to buy or sell our securities and to obtain accurate quotations, and the price of our securities could suffer a material decline. Delisting could also impair the liquidity of our common stock and could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in potential loss of confidence by investors, employees, and fewer business development opportunities.

3937

Table of Contents

Item 6. Exhibits.

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which is incorporated herein by reference.

Exhibit Index


Exhibit
Number		Description of Document
3.1		Amended and Restated Bylaws of Agile Therapeutics, Inc., effective as of January 25, 2023 (Incorporated by reference, Exhibit 3.1 to Company’s Current Report on Form 8-K, file number 001-36464, filed on January 26, 2023.)

3.2		Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock filed with the Secretary of State of the State of Delaware on January 26, 2023 (Incorporated by reference, Exhibit 3.2 to Company’s Current Report on Form 8-K, file number 001-36464, filed on January 26, 2023.)

3.3		Certificate of Amendment to Amended and Restated Certificate of Incorporation, as filed with the Secretary of the State of Delaware on April 10, 2023 (Incorporated by reference, Exhibit 3.1 to Company’s Current Report on Form 8-K, file number 001-36464, filed on April 10, 2023.)

4.1		~~Form~~Amended and Restated Common Stock Purchase Warrant between Agile Therapeutics, Inc. and Perceptive Credit Holdings III, LP, dated as of ~~Series A-1 Warrant (incorporated~~March 21, 2023 (Incorporated by reference, Exhibit ~~4.1~~4.2 to ~~the~~ Company’s ~~Current~~Annual Report on Form ~~8-K,~~10-K, file number 001-36464, filed on ~~July 8, 2022.~~March 23, 2023.)

4.2		~~Form~~Amended and Restated Common Stock Purchase Warrant between Agile Therapeutics, Inc. and Perceptive Credit Holdings III, LP, dated as of ~~Series A-2 Warrant (incorporated~~March 21, 2023 (Incorporated by reference, Exhibit ~~4.2~~4.3 to ~~the~~ Company’s ~~Current~~Annual Report on Form ~~8-K,~~10-K, file number 001-36464, filed on ~~July 8, 2022.~~March 23, 2023.)

4.3		~~Form~~Amended and Restated Common Stock Purchase Warrant between Agile Therapeutics, Inc. and Perceptive Credit Holdings III, LP, dated as of ~~Series B Pre-Funded Warrant (incorporated~~March 21, 2023 (Incorporated by reference, Exhibit ~~4.3~~4.4 to ~~the~~ Company’s ~~Current~~Annual Report on Form ~~8-K,~~10-K, file number 001-36464, filed on ~~July 8, 2022.~~March 23, 2023.)

~~4.4~~10.1*		~~Form of Placement Agent Warrant (incorporated~~Sixth Amendment to Project Agreement, dated January 3, 2023, by and between Agile Therapeutics, Inc. and inVentiv Commercial Services LLC (Incorporated by reference, Exhibit ~~4.4~~10.27 to the Company’s ~~Current~~Annual Report on Form ~~8-K,~~10-K, file number 001-36464, filed on ~~July 8, 2022.~~March 23, 2023.)

~~10.1~~10.2		~~Fifth~~Waiver and Sixth Amendment to Credit Agreement and Guaranty among Agile Therapeutics, Inc., the guarantors from time to time party thereto, the lenders from time to time party thereto and Perceptive Credit Holdings III, LP, dated as of ~~July 25, 2022.~~

~~10.2~~		Amendment No. 1 to Manufacturing and Commercialization Agreement, by and between Corium, Inc. and Agile Therapeutics, Inc., dated as of July 25, 2022, and Bill of Sale by Agile Therapeutics, Inc. to Corium, Inc., dated as of July 25, 2022.

~~10.3~~		~~Form of Securities Purchase Agreement, by and between Agile Therapeutics, Inc. and certain purchasers (incorporated~~March 21, 2023 (Incorporated by reference, Exhibit ~~10.1~~10.18 to ~~the~~ Company’s ~~Current Report~~Registration Statement on Form ~~8-K,~~S-1, file number ~~001-36464,~~333-271249, filed on ~~July 8, 2022.~~April 14, 2023.)

31.1		Certification of the Registrant’s Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Registrant’s Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of the Registrant’s Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of the Registrant’s Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended ~~September 30, 2022~~March 31, 2023 formatted in Inline Extensible Business Reporting Language (XBRL): (i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders’ Equity (Deficit), (v) Statements of Cash Flows, and (vi) the Notes to Financial Statements.

Table of Contents

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Portions of the exhibit have been redacted in accordance with Regulation S-K Item 601(b)(10).

** The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates them by reference.

4039

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: ~~November 7, 2022~~May 11, 2023	Agile Therapeutics, Inc.

	By:	/s/ Alfred Altomari
		Alfred Altomari
		President and Chief Executive Officer (Principal Executive Officer)


Date: ~~November 7, 2022~~May 11, 2023

	By:	/s/ Jason Butch
		Jason Butch
		Vice President and Chief Accounting Officer (Principal Financial Officer)

4140


2022	$	66
2023		390
2024		398
2025		100
Total	$	954
Less: Interest		(127)
Present value of lease liability	$	827


	Nine Months Ended September 30,
	(In thousands)
	2022		2021

Net cash used in operating activities	$	(34,388)	$	(48,584)
Net cash (used in) provided by investing activities		(133)		39,515
Net cash provided by financing activities		21,523		9,341
Net (decrease) increase in cash and cash equivalents	$	(12,998)	$	272